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ABSTRACT 
Dyslipidemia, defined as abnormal levels of plasma lipids, is an independent risk 
factor for cardiovascular diseases, and is increasing worldwide. Methylglyoxal (MG), 
a reactive glucose metabolite, is a causative factor for type 2 diabetes and is 
associated with hypertension. We have recently reported abnormal plasma lipid levels 
in Sprague-Dawley (SD) rats treated chronically with MG. The liver and the adipose 
tissue are the main organs that contribute to plasma lipid level regulation. The aim of 
this study was to explore the possible mechanism(s) of MG-induced dyslipidemia. 
MG (60 mg/kg/day) or 0.9% saline was administered to 12-week-old male SD rats by 
continuous infusion with a minipump for 28 days and thereafter, the liver, and the 
adipose tissue were isolated and the plasma was collected. We also used cultured 
3T3-L1 adipocytes for molecular studies. We performed Oil-Red O staining and 
hematoxylin-eosin staining, ELISA, western blotting and quantitative PCR. In the 
liver of rats treated chronically with MG, there was increased protein expression of 
sterol regulatory element binding protein-2 (SREBP-2), 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase and microsomal triacylglycerol transfer protein 
(MTP), with no change in SREBP-1 and low density lipoprotein (LDL) receptor. In 
the adipose tissue, MG treated rats showed enlarged abdominal adipocytes, and 
increased protein expression and/or mRNA of CCAAT-enhancer binding protein 
(C/EBP)α, C/EBPβ and tumor necrosis factor alpha (TNFα), with no significant 
change in peroxisome proliferator activated receptor gamma (PPARγ), adiponectin, leptin 
and lipoprotein lipase levels. The effects of MG were attenuated by aminoguanidine, a 
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MG and an advanced glycation endproducts scavenger. The findings in adipose tissue 
were confirmed in cultured 3T3-L1 cells. Our results indicate that the increase in 
plasma cholesterol and triacylglycerols by MG may be due to increased activity of 
hepatic SREBP-2 and HMG-CoA reductase, and the subsequent increased cholesterol 
synthesis; and due to increased activity of MTP and the resultant increased VLDL 
synthesis. The increase in plasma free fatty acids may be due to increased 
triacylglycerol accumulation caused by over-expression of C/EBPα and C/EBPβ, 
increased adipocyte size and up-regulated gene expression of TNFα, and the resultant 
decreased free fatty acids uptake and increased lipolysis in adipocytes. 
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CHAPTER ONE 
INTRODUCTION 
1.1 Dyslipidemia  
1.1.1 Definition 
Dyslipidemia, characterized as (a) elevated fatty acids in the circulation, (b) raised 
triacylglycerol (TG) values, (c) low high density lipoprotein (HDL) cholesterol levels, 
(d) increased small, dense low density lipoprotein (LDL) levels and (e) elevated 
apolipoprotein (apo) B levels, is widely established as an independent risk factor for 
cardiovascular diseases (CVD) (Kolovou et al. 2005). However, most individuals who 
develop CVD have multiple risk factors that commonly cluster together, such as 
dyslipidemia, hypertension and hyperglycemia and the term metabolic syndrome has 
been given to this phenomenon (Grundy et al. 2004).  
 
1.1.2 Prevalence 
According to the 2009 update of the Canadian Cardiovascular Society (CCS) 
guidelines for the diagnosis and treatment of dyslipidemia and prevention of 
cardiovascular disease in the adult (Genest et al. 2009), cardiovascular disease (CVD) 
is the leading reason for deaths in Canada which accounts for one-third of deaths. The 
prevalence of CVD in Canada is expected to increase predominantly because of the 
prevalence of sedentary lifestyles and emergence of obesity and diabetes mellitus in 
epidemic proportions.  
Data from the National Health and Nutrition Examination Survey (NHANES) from 
2003-2006 in United States showed that there are approximately 34% of adults who 
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meet the criteria for the metabolic syndrome. People with older age or higher body 
mass index (BMI) were much more likely to meet the criteria compared to those aged 
20-39 or with normal body weight, respectively (Ervin. 2009). 
There are at least 3 organizations that have recommended clinical criteria for 
metabolic syndrome. They included similar aspects but have notable differences 
(Grundy et al. 2004). The 2009 CCS guidelines (Genest et al. 2009) have quoted the 
criteria from the International Diabetes Federation (IDF) while the NHANES used the 
one from the National Cholesterol Education Program's Adult Treatment Panel III 
(NCEP/ATP III) guidelines as metabolic syndrome criteria (Ervin. 2009) (Table 1-1). 
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IDF 
Central obesity   
 Waist circumference 
Europeans Men≥94 cm; Women≥80 cm 
South Asians Men≥90 cm; Women≥80 cm 
Chinese Men≥90 cm; Women≥80 cm 
Japanese Men≥90 cm; Women≥80 cm 
Ethnic South and Central Americans Use South Asian recommendations until 
more specific data are available 
First Nations Use South Asian recommendations until 
more specific data are available 
Sub-Saharan Africans Use European data until more specific 
data are available 
Eastern Mediterranean and Middle East 
(Arabic) Populations 
Use European data until more specific 
data are available 
Plus two of the following factors:  
Plasma triacylglycerols                           >1.7 mmol/L 
HDL cholesterol Men<1.03 mmol/L; Women<1.3 mmol/L 
Blood Pressure >130/85 mmHg(or treatment for 
hypertension) 
Fasting plasma glucose >5.6 mmol/L 
NCEP/ATPIII 
At least of three of following factors  
Waist circumference Men>102 cm; Women>88 cm 
Fasting triacylglycerols ≥1.7 mmol/L 
HDL cholesterol Men<1 mmol/L; Women<1.3 mmol/L 
Blood Pressure ≥130/85 mmHg 
Fasting glucose ≥6.1 mmol/L 
 
Table 1-1. Metabolic syndrome criteria defined by the International Diabetes 
Federation (IDF) and the National Cholesterol Education Program’s Adult 
Treatment Panel III (NCEP/ATPIII). The table is modified from 2009 Canadian 
Cardiovascular Society (CCS) guidelines (Genest et al. 2009) and National Health and 
Nutrition Examination Survey (Ervin. 2009). HDL, High density lipoproteins. 
 
1.1.3 Pathogenesis 
Primary dyslipidemia is mainly due to genetic disorders such as defects in LDL 
receptor or lipoprotein lipase, whereas secondary dyslipidemia mainly results from 
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unhealthy lifestyle such as sedentary behavior and diets high in carbohydrates, and 
saturated fat (Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12e, 
chapter 31). In addition, environmental factors, medications, drugs, hormones, or even 
other diseases can cause secondary dyslipidemia.  
Familial combined hyperlipidemia (FCHL) is the most common genetic form of 
dyslipidemia and is associated with 1.7 to 10 times increase in the risk of coronary 
artery disease (CAD) (Carr and Brunzell. 2004). Compared to the lipid disturbance 
involved in most metabolic syndrome patients, FCHL patients exhibit exaggerated 
high plasma triacylglycerol as well as increased plasma apoB and increased number 
of small dense LDL particles. The reason or the major gene for FCHL has not been 
clearly defined. However, besides the decrease in lipoprotein lipase (LPL) activity and 
predisposition of central abdominal fat, researchers also suggest that there exists a 
gene(s) associated with increased apoB levels (Ayyobi and Brunzell. 2003). 
However, the majority of dyslipidemia cases are secondary. Take high-fat and high 
carbohydrates diets as examples. Saturated fat intake is thought to increase the 
concentration of LDL cholesterol and therefore increase the risk of CVD. In the 
United States, the major dietary sources of saturated fatty acids are full-fat dairy 
products and red meat (Siri-Tarino et al. 2010). The increased consumption of calories, 
especially in the form of refined carbohydrates is recognized to be highly correlated 
with the increase of metabolic syndrome (Basciano et al. 2005). Fructose is widely 
used in sweeteners nowadays and its consumption has increased 5 fold in the last 
century and doubled in the last 30 years (Lustig. 2010). A numbers of studies have 
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provided the evidence that over-consumption of fructose is associated with increased 
TG production and lipoprotein (VLDL and resultant LDL) secretion and the possible 
mechanisms have been nicely reviewed by Basciano et al (Basciano et al. 2005). 
Alarms have been raised on the over-consumption of saturated fats and high 
carbohydrate diet-induced dyslipidemia as well as obesity and the metabolic 
syndrome. For reducing the risks and improving health, dietary strategies including 
reduced postprandial glucose and triacylglycerol, increased intake of dietary 
antioxidants, potassium (for lowering the blood pressure), and unsaturated fatty acids 
such as omega-3 fatty acids have been suggested (O'Keefe and Abuannadi. 2010). 
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1.2 Plasma lipid sources and cycling  
1.2.1 Types of lipids 
  Lipids, insoluble fatty substances, can be classified into simple lipids, such as 
cholesterol and fatty acids, and complex lipids, including cholesterol esters and 
glycerol esters such as triacylglycerols. The major function of lipids is to serve as a 
source of energy for the body. Other important functions include forming cell 
membranes, synthesis of hormones and vitamins, synthesis of bile acids, protecting 
vital organs from physical forces and providing insulation. 
Cholesterol is a common simple lipid. It is a steroid alcohol comprised of a 
four-ringed steroid nucleus and a hydroxyl group. Cholesterol exists as a free sterol in 
cell membranes, but as an ester combined with a long-chain fatty acid in the plasma. 
Cholesterol is essential for human and other vertebrates because of its important role 
in creating signaling molecules on the plasma membrane, synthesis of all steroid 
hormones and bile acids as well as forming the myelin sheath which surrounds axons. 
(Goldstein and Brown. 2009). 
Because of limited production in our body, most fatty acids must be obtained from 
the diet (Mattson and Grundy. 1985). There are three forms of fatty acids: saturated, 
monounsaturated and polyunsaturated, which can be distinguished by the number of 
double bonds between the carbon atoms in the hydrocarbon chain. 
There are three basic classes of complex lipids: triacylglycerols, phospholipids, and 
cholesterol esters. A triacylglycerol is formed by the esterification of glycerol with 
three fatty acid molecules. Most triacylglycerols are stored in adipose tissue as an 
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emergency energy source. When carbohydrate energy sources in our bodies are 
depleted, triacylglycerols will release fatty acids to meet the need of energy. 
 
1.2.2 Structure of Lipoproteins 
Since cholesterol and triacylglycerols are insoluble in the water, they must be 
modified in order to be transported in the blood. Apolipoproteins combine with the 
lipids to form soluble complexes named lipoproteins (Fredrickson et al. 1972) (Figure 
1-1). Each lipoprotein is a sphere with a surface primarily formed by phospholipids 
and a hydrophobic core containing triacylglycerols and cholesteryl esters. There are 
two ends in each phospholipid: a hydrophobic end pointing into the lipid core, and a 
hydrophilic end which is soluble in plasma. An apolipoprotein, which stabilizes the 
lipoprotein structure, is located in the outer shell. Moreover, apolipoproteins can be 
recognized by specific receptors that metabolize them. 
 
 
Figure 1-1. Structure of lipoprotein. (Source: Available online at: 
http://web.campbell.edu/faculty/nemecz/323_lect/fatty_acid/images/struct_2.jpg). 
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1.2.3 Characteristics of lipoproteins 
  Six types of lipoproteins are classified by different factors including density, 
composition and apoproteins. Different types of lipoproteins transport specific lipids 
from synthesis sites to utilization sites. This is summarized in the table (Table 1-2). 
 
Lipoprotein  
class 
Density 
(g/mL) 
Major lipid 
constituent 
TG: 
CHOL 
ratio 
Significant 
apoproteins 
Site of  
synthesis 
Mechanism(s) of  
catabolism 
Chylomicrons 
and remnants 
≤1.006 Dietary 
triacylglycerol
s and 
cholesterol 
10:1 B-48,E, 
A-I,A-IV, 
C-I, 
C-II,C-III 
Intestine Triacylglycerol 
hydrolysis by 
LPL, 
apoE-mediated 
remnant uptake by 
the liver 
VLDL <1.006 “Endogenous” 
or hepatic 
triacylglycerol
s 
5:1 B-100,E, 
C-I, 
C-II,C-III 
Liver  Triacylglycerol 
hydrolysis by LPL 
IDL 1.006-1.
019 
Cholesteryl 
esters and 
“endogenous” 
triacylglycerol
s 
1:1 B-100,E, 
C-II,C-III 
Product of 
VLDL 
catabolism 
50% converted to 
LDL mediated by 
HL; 50% 
apoE-mediated 
uptake by the liver 
LDL 1.019-1.
063 
Cholesteryl 
esters 
NS B-100 Product of 
VLDL 
catabolism 
ApoB-100–mediat
ed uptake by LDL 
receptor (75% in 
the liver) 
HDL 1.063-1.
21 
Phospholipids 
cholesteryl 
esters 
NS A-I,A-II, 
C-I, 
C-II,C-III 
Intestine, 
liver, 
plasma 
Complex: transfer 
of cholesteryl ester 
to VLDL and 
LDL; uptake of 
HDL cholesterol 
by hepatocytes 
Lipoprotein(a) 1.05-1.0
9 
Cholesteryl 
esters 
NS B-100, 
apo(a) 
Liver Unknown 
 
Table 1-2. Characteristics of Plasma Lipoproteins  
Abbreviations: apo, apolipoprotein; CHOL, cholesterol; HDL, high-density lipoproteins; 
IDL, intermediate-density lipoproteins; LDL, low-density lipoproteins; NS, not significant 
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(triacylglycerol is <5% of LDL and HDL); TG, triacylglycerol; VLDL, very-low-density 
lipoproteins; HL, hepatic lipase; LPL, lipoprotein lipase. (Source: Goodman Pharmacology 
12edition). 
 
1.2.4 Lipoprotein metablic pathways 
  Lipoprotein metabolism consists of 3 separate but integrated pathways that involve 
the liver, the primary organ of lipid metabolism and also other organs such as small 
intestines, adipose tissue and muscle. The 3 pathways include the exogenous pathway, 
the endogenous pathway (Fig 1-2) and the reverse cholesterol transport pathway 
(Schaefer et al. 1978; Kwiterovich. 2000). 
  Lipids from the food are metabolized via the exogenous pathway (Fig 1-2). Dietary 
fat breaks down into fatty acids and cholesterol in the gastrointestinal tract and then is 
converted into triacylglycerols and cholesterol esters, respectively. Within the 
intestine, triacylglycerols and cholesterol are incorporated into chylomicrons for 
transport in the blood and delivered to muscles and adipose tissue through capillaries. 
There, lipoprotein lipase (LPL) breaks down the triacylglycerols into free fatty acids 
(FFAs). After removing triacylglycerols from the chylomicrons, the resultant 
chylomicron remnants with relatively high cholesterol concentration are then 
extracted by the liver from the blood which is mediated by the interactions between 
apoE on the surface of the chylomicron particles and two receptors on liver cells: the 
LDL receptor and the LDL receptor-related protein (LRP). Inside the liver cells, the 
cholesterol from the chylomicron remnants is either stored in the liver or is used to 
synthesize bile acids, cell membranes, or other lipoproteins. 
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  Lipids synthesized in the liver are metabolized via the endogenous pathway (Fig 
1-2). VLDL, the primary lipoprotein produced by the liver, is broken down by LPL 
into FFAs in a way similar to chylomicron degradation. The resultant IDL then 
processed in two ways: 1. Binding with the liver LDL receptors which leads to 
intracellular metabolism. Approximately 50% of the IDL particles are rapidly 
removed from the circulation in this way; 2. The remaining IDL particles in the blood 
are gradually taken up by the liver LDL receptors and then converted to LDL by liver 
hepatic lipase (HL). Most LDL is removed from the blood by the liver LDL receptor 
and excreted via the enterohepatic circulation (Goldstein and Brown. 1992). 
 Reverse cholesterol transport is the process by which the cholesterol from the 
tissues is transported back to the liver, which reuses cholesterol. HDL particles are 
central to reverse cholesterol transport (Remaley. 2011; Rayner et al. 2011).  
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Figure 1-2. The exogenous and endogenous lipoprotein metabolic pathways.  
LPL, lipoprotein lipase; FFA, free fatty acid; VLDL, very low density lipoprotein; 
IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; LDLR, 
low-density lipoprotein receptor; Apo C‟s, Apolipoprotein C-I, C-II, C-III, and C-IV; 
ApoB, Apolipoprotein B; Apo E, Apolipoprotein E. 
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1.3 Adipose tissue and lipid regulation 
1.3.1 Adipose tissue types  
Adipose tissue was first considered simply as a triacylglycerol storage organ.  
However studies through recent two decades have demonstrated that the adipocyte is  
a dynamic cell that plays an important role in energy balance and whole body 
homeostasis (Deng and Scherer. 2010).The reasons that account for these newly found 
functions of adipose tissue include the facts that the adipose tissue is now known to 
secret a series of bioactive adipokines such as leptin, adiponectin and tumor necrosis 
factor alpha (TNFα) which act both locally and at the systemic level; the adipose 
tissue expresses a number of receptors such as insulin receptor, leptin receptor and 
TNFα receptor and therefore it is able to respond to various signals from both the 
hormonal system and the central nervous system (Kershaw and Flier. 2004) 
There are two types of adipose tissues in mammals, white adipose tissue (WAT) and 
brown adipose tissue (BAT). They differ in several major features (see table). In 
rodents, most BAT is located in the interscapular region; in humans, large depots of 
BAT are found in infancy, but only small amounts persist in adults. In addition, BAT 
expresses almost all the genes that are expressed in WAT, but they also express some 
distinct genes including uncoupling protein-1 (UCP1), which is located in the 
mitochondria of BAT and is responsible for its thermogenesis function without 
generating ATP (Rosen and MacDougald. 2006). 
WAT is distributed throughout the body in the form of two major types, 
subcutaneous adipose tissue and visceral (or abdominal) adipose tissue. Besides the 
13 
 
difference in locations, they possess distinct physiological properties. Increased 
visceral adipose tissue, that is central obesity, has been found to be associated with an 
increased risk for developing conditions such as insulin resistance, type 2 diabetes 
mellitus, dyslipidemia, hypertension, atherosclerosis, hepatic steatosis and cholesterol 
gallstones. By contrast, increased subcutaneous adipose tissue mass predominantly in 
buttocks and thighs, that is peripheral obesity, seems to be associated with improved 
insulin sensitivity and a lower risk of developing type 2 diabetes mellitus compared to 
those with central obesity (Tran and Kahn. 2010). Various reasons have been proposed 
to explain the protective and detrimental effect of subcutaneous adipose tissue and 
visceral adipose tissue, respectively (Tran and Kahn. 2010), and the greater 
antilipolytic effect to insulin in subcutaneous adipose tissue is one of them. 
 
Major feature WAT BAT 
Vascularization Some, limited Extensive 
Distribution Extensive, many sites Restricted 
Sympathetic innervation Some, limited Extensive 
Fatty acid role(s) Synthesis, storage, 
signaling 
Storage, oxidation, 
signaling 
Thermogenesis Negligible Highly developed 
Insulin effects Extensive Extensive 
Adrenoreceptors Primarily α2,β1,β2,β3 Primarily α1,β1,β3 
Droplet size Large, single Small, multiple 
Mitochondria few Many, densely packed 
 
 
Table 1-3. Comparison of major features of white and brown adipose tissue. 
(Source: Dennis E. Vance and Jean E. Vance, Biochemistry of lipids, lipoproteins and 
membranes 5th edition, chapter 10) 
14 
 
1.3.2  Adipocyte differentiation 
Adipocytes derive from mesenchymal stem cells which are pluripotent cells with 
the capacity to differentiate into limited cell types, including myocytes, chondrocytes, 
osteocytes and adipocytes. There are two phases of adipogenesis. The first phase is 
called determination, in which mesenchymal stem cells convert to fibroblast-like 
pre-adipocytes and lose the potential to differentiate into other cell types. This 
conversion cannot be distinguished morphologically. The second phase is known as 
terminal differentiation, in which the pre-adipocytes take on characteristics of the 
mature adipocytes which are essential for lipid transport and synthesis, insulin 
sensitivity and adipokine secretion (Rosen and MacDougald. 2006). 
Compared to the first phase, the phase of terminal differentiation has been more 
extensively studied by using both cell line and primary cell models. After growth 
arrest at confluence, a variety of differentiation protocols which may include 
endocrine, paracrine regulators and/or transcription factors have been used for 
inducing differentiation for different cell models (Gregoire et al. 1998; Hwang et al. 
1997). For example, the most well developed and frequently used cell lines are mouse 
pre-adipocyte cell lines 3T3-L1 and 3T3-F422A, which were clonally isolated from 
Swiss 3T3 cells derived from disaggregated 17- to 19- day mouse embryos (Rosen 
and MacDougald. 2006; Gregoire et al. 1998). The combination of 10% fetal bovine 
serum (FBS), insulin, dexamethasone (Dex, a glucorticoid) and 
methylisobutylxanthine (MIX, an agent that increases the intracellular cAMP level) 
has been proven to be the most effective for differentiating 3T3-L1 cell lines while 
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only FBS and insulin are needed for 3T3-F442A (Hwang et al. 1997; Student et al. 
1980) 
During adipocyte differentiation, chronological changes of expression of numerous 
genes demonstrate the acquisition of the adipocyte phenotype (Hwang et al. 1997). 
Moreover, alteration of these genes during differentiation or in the mature adipocyte 
could lead to physiological dysfunction. These will be explained specifically later. 
 
1.3.3  CCAAT/enhancer binding protein family (C/EBPs)  
C/EBPs are expressed in various tissues and are involved in the regulation of 
several biological processes, including control of energy metabolism. In adipose 
tissue, C/EBPs were the first transcription factors demonstrated to play a major role in 
the regulation of adipocyte differentiation. These factors are proteins belonging to the 
bZIP class, with a transcriptional activation domain and a leucine zipper motif (Hurst. 
1995). 
C/EBPβ and C/EBPδ are likely functional in the early stage of differentiation. 
cAMP and glucocorticoid are applied to induce cultured adipocyte differentiation and 
seem to be directly responsible for the induction of C/EBPβ and C/EBPδ, respectively 
(Yeh et al. 1995). At the late differentiation phase, the expression of C/EBPβ dropped 
50% from its maximal level which it reached within the first 2 days, and C/EBPδ 
dropped even more sharply (Cao et al. 1991). The major role of these two C/EBPs 
seems to be the induction of C/EBPα and PPARγ (Wu et al. 1996; Hamm et al. 2001). 
C/EBPα is another C/EBP isoform induced relatively late in the adipocyte 
16 
 
differentiation process and just prior to the expression of many adipocyte-specific 
genes (Cao et al. 1991). C/EBPα is required to induce adipocyte and recognized to 
play a central role in the regulation of energy homeostasis since the expression of 
anti-sense C/EBPα in 3T3-L1 pre-adipocytes blocked the differentiation process (Lin 
and Lane. 1992), and C/EBPα knockout mice also failed to accumulate lipid in 
adipocyte and died from hypoglycemia within 8 hours of birth (Wang et al. 1995). 
Moreover, C/EBPα could bind and transactivate the promoter of several 
adipocyte-specific genes (Gregoire et al. 1998). For example, the mutation of C/EBPα 
site in leptin blocked its transactivation (Hwang et al. 1996). 
Unlike C/EBPβ and C/EBPδ, C/EBPα is expressed at high levels in the mature 
adipocyte and adipose tissue (Cao et al. 1991). Insulin regulates the transcription of 
C/EBP genes in mature adipocytes. Adding insulin to 3T3-L1 adipocytes repressed 
the expression of C/EBPα while it induced the expression of C/EBPβ and C/EBPσ 
(MacDougald et al. 1995a).  
 
1.3.4  Peroxisome proliferator-activated receptor gamma (PPARγ) 
The PPARs belong to a class of nuclear hormone receptors and form heterodimers 
by binding with the retinoid X receptors (RXRs) (Juge-Aubry et al. 1995). PPARγ, 
expressed during the early stages of adipocyte differentiation, has been shown to be 
the most adipose specific and most adipogenic of the three PPAR isoforms: α, σ/β, γ 
(Braissant et al. 1996). Compared to PPAR γ1, the other PPARγ isoform, PPARγ2 is 
more predominantly expressed in adipose tissue (Zhu et al. 1995; Tontonoz et al. 
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1994). PPARγ is thought to be a master regulator of adipogenesis. PPARγ and 
C/EBPα cross-regulate each other‟s expression and govern expression of the entire 
adipogenic program (Farmer. 2005). A study in type 2 diabetic patients treated with 
thiazolidinediones (TZDs, PPARγ agonists), showed improved insulin sensitivity, but 
increased weight gain (Fonseca. 2003). Moreover, an ex vivo study in rats showed that 
TZDs induce remodeling of visceral adipocytes to a smaller size with higher lipid 
storage potential (de Souza et al. 2001) and an in vivo study in wild type mice showed 
that TZD treatment prevented high-fat induced adipocyte hypertrophy but not insulin 
resistance (Miles et al. 2003).  
Failure of insulin to suppress lipolysis leads to elevated blood triacylglycerol levels 
as well as decreased HDL levels. A review summarized that subjects with mutation in 
PPARγ have shown elevated triacylglycerols and low HDL levels, without significant 
change in LDL levels (Gurnell et al. 2003). PPARγ agonists, which improve insulin 
sensitivity, decrease FFA levels mostly by promoting the storage of FFA in adipocyte 
(Martin et al. 1998). However, although pioglitazone does reduce triglylcerides, 
rosiglitazone does not lower and may even slightly increase serum triacylglycerol 
levels (Gurnell et al. 2003). 
In addition to the impact on obesity, insulin resistance and dyslipidemia, PPARγ 
activation in adipose tissue is also associated with the expression of a wide range of 
adipokines in a beneficial way, including adiponectin, leptin and TNFα. PPARγ 
activation up-regulates the expression of adiponectin, which appears to be an 
important mediator of PPARγ agonist-induced improvement of insulin sensitivity 
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(Bouskila et al. 2005). Moreover, PPARγ agonists suppress the production of leptin 
and TNFα (Hammarstedt et al. 2005; Kallen and Lazar. 1996). 
 
1.3.5  Tumor necrosis factor alpha (TNFα)  
TNFα, a 17-KDa polypeptide, is an inflammatory cytokine first found in the 
supernatant of cultured macrophages and later reported to be also highly induced in 
the adipose tissue in both animals and humans (Kawakami and Cerami. 1981; 
Kawakami et al. 1982; Hotamisligil et al. 1993; Hotamisligil et al. 1995). 
Adipocyte-derived TNFα has been linked to dyslipidemia in both clinical and basic 
studies. Patients with higher TNFα concentration in plasma showed increased levels 
of total cholesterol, TG and LDL (Madej et al. 1998). Meanwhile, HMG-CoA 
reductase inhibitors such as simvastatin and atorvastatin that are used for 
hyperlipidemia could decrease plasma TNFα levels (Ascer et al. 2004; Marketou et al. 
2006). 
In the review by Sethi and Hotamisligil (Sethi and Hotamisligil. 1999), three 
aspects of TNFα involved in the regulation of lipid metabolism have been 
summarized: 1. Elevated TNFα contributes to elevated basal lipolysis rate which leads 
to increased FFA levels in the circulation; 2. TNFα could decrease FFA uptake from 
the circulation and contribute to hyperlipidemia by inhibiting activity and 
down-regulating the protein expression of LPL and expression of FFA transporters 
such as fatty acid transport protein (FATP); 3. TNFα decreases the expression of key 
enzymes involved in lipogenesis including perilipin and hormone sensitive lipase 
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(HSL), however this may not happen in mature adipocytes (Figure 1-5). In addition, 
TNFα could also affect lipid metabolism by altering related adipokines, such as leptin 
and adiponectin (Finck and Johnson. 2000; Hector et al. 2007; Li et al. 2009). PPARγ, 
which has been described before, exhibited opposite effects to TNFα on the 
expression of certain proteins involved in adipocyte lipid regulation. Those proteins 
are also indicated in Figure 1-5. 
 
Figure 1-3. Tumor necrosis factor alpha (TNFα) regulates lipid metabolism in 
the adipocytes. The net action of TNFα in adipocytes is to decrease FFA uptake and 
triacylglycerol synthesis (lipogenesis) as well as increase lipolysis. An asterisk 
indicates proteins whose activity and/or expression is down-regulated by TNFα but 
up-regulated by PPARγ and its ligands. Lipogenic enzymes such as acetyl-CoA 
carboxylase and fatty acid synthetase are also included. 
Abbreviations: LPL, lipoprotein lipase; FFA, free fatty acids; FATP, fatty acid 
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transporter protein; aP2, adipocyte fatty acid binding protein; ACS, acyl-CoA 
synthetase; HSL, hormone sensitive lipase; βAR, β3 adrenergic receptor; AC, 
adenylate cyclase; PKA, protein kinase A; Glut 4, insulin sensitive glucose transporter. 
(Source: Sethi and Hotamisligil. 1999) 
 
1.3.6 Lipoprotein lipase (LPL)  
LPL plays a crucial role in lipid metabolism and transport by catalyzing the 
rate-limiting step in hydrolysis of triacylglycerol, present in the circulating 
chylomicrons and VLDL, to FFAs which are further synthesized to triacylglycerol in 
the adipocyte (Weinstock et al. 1997). Besides adipose tissue, other major synthesis 
sites for LPL are cardiac, skeletal muscle and the lactating mammary gland, with 
limited expression in many other tissues (Mead et al. 2002). However, LPL is 
recognized as an extra-hepatic enzyme since the expression of LPL in the liver is 
terminated soon after birth (Staels and Auwerx. 1992). 
The reaction site for LPL-mediated hydrolysis is at the luminal surface of capillary 
endothelium. However, translocation happens before LPL reaches the site of action 
(Braun and Severson. 1992). Briefly, LPL mRNA is translated in the rough 
endoplasmic reticulum (ER), and then transported to the Golgi apparatus. From Golgi 
apparatus, it is first delivered to the secretory vesicles, and thereafter either to the 
lysosomes for intracellular degradation or to the parenchymal cell surface. After that, 
it finally translocated to the capillary endothelial cell surface. In an ex vivo study, Roh 
et al. (Roh et al. 2001) found that both LPL activity and protein levels are high in the 
ER with only a small fraction present in low density secretory vesicles in rat 
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adipocytes. 
LPL expression is regulated by a number of factors in physiological and 
pathophysiological conditions which have been well summarized in the review by 
Mead et al. (Mead et al. 2002). Take insulin and TNFα as examples, insulin increased 
LPL activity without affecting its mRNA levels in cultured 3T3-L1 cells while TNFα 
lowered both LPL activity and mRNA levels in 3T3-L1 cells.  
As a central enzyme in lipid metabolism, LPL is implicated in a number of diseases 
either directly or indirectly, such as chylomicronaemia, obesity, atherosclerosis, 
Alzheimer‟s disease and dyslipidemia associated with diabetes and insulin resistance. 
In type 2 diabetes and insulin resistance patients, decreased adipose tissue LPL 
activity was found (Pykalisto et al. 1975; Simsolo et al. 1992). Moreover, elevated 
production of cytokines such as TNFα results in a reduction in LPL expression and 
activity, which contributes to the hypertriglyceridaemia (Kern. 1997; Halle et al. 
1998). 
 
1.3.7 Leptin 
Leptin, the 16-KDa product of obese (ob) gene, was the first adipokine discovered 
by Friedman and his group in 1994 (Zhang et al. 1994). Leptin is secreted almost 
exclusively by the adipose tissue. The major role of leptin is to balance body energy 
by repressing food intake and increasing energy expenditure by signaling to the 
central nervous system (CNS) (Havel. 2004; Porte et al. 2002; Rosen and Spiegelman. 
2006b; Havel. 2001). 
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Transcription of the ob gene appears to be activated by C/EBPα during adipocyte 
differentiation (Miller et al. 1996). Meanwhile, a number of studies found that the 
expression of leptin is regulated by a range of factors, such as insulin, cAMP, 
glucocorticoids, TNFα and PPARγ agonists. To be specific, insulin, glucocorticoids 
and TNFα increased the leptin expression both in vivo and in cultured adipocytes 
(MacDougald et al. 1995b; Slieker et al. 1996a; Murakami et al. 1995; Medina et al. 
1999). As a counter-regulator to the effect of insulin, cAMP lowered leptin mRNA 
levels (Slieker et al. 1996). TZDs and PPARγ agonists also suppress leptin gene 
expression (Kallen and Lazar. 1996). 
Mutations of ob gene or defects in the leptin receptor lead to extreme hyperphagia 
and obesity. Treatment with recombinant leptin reduces the hyperphagia and induces 
weight loss in leptin-deficient subjects (Havel. 2004). A lipoatrophic diabetes mouse 
model exhibits marked insulin resistance and hyperlipidemia, which is also effectively 
reversed by the administration of leptin (Ebihara et al. 2001). Serum leptin level is 
positively correlated to total body fat mass in humans which could be explained by 
increased release of leptin in large fat cells compared to small ones since fat cell size 
is usually 2-4 times larger in the obese subjects compared to the normal subjects. In 
addition, leptin has complex interactions with the lipid and lipoprotein metabolism in 
different glycemic conditions (Singh et al. 2010) and leptin has been found to have an 
inverse relationship with plasma HDL level in humans (Rainwater et al. 1997). 
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1.3.8 Adiponectin  
Adiponectin, a 30-KDa protein, is found to be produced exclusively by adipose 
tissue and circulate at extraordinarily high concentrations. Plasma adiponectin levels 
in humans range from 0.5-30 μg/ml, which is about 1000 fold higher than leptin and 
most other adipokines and thus is known as the most abundant adipose tissue protein 
(Rosen and Spiegelman. 2006b; Haluzik et al. 2004). Unlike all the other current 
known adipokines, clinical studies have shown that adiponectin levels in the plasma 
are negatively correlated with BMI (Arita et al. 1999; Yatagai et al. 2003). 
Several factors were reported to regulate adiponectin gene expression. The 
expression of adiponectin in WAT is decreased by obesity, TNFα, β-adrenergic 
stimulation and glucocorticoids, and increased by leanness, cold exposure, and PPARγ 
agonists (Haluzik et al. 2004; Combs et al. 2002). Insulin is an important regulator of 
adiponectin gene expression and different effects have been shown under different 
doses and durations of action by in vitro studies (Haluzik et al. 2004) . 
Besides decrease in obese patients, plasma adiponectin was also found decreased in 
type 2 diabetic individuals as compared to non-diabetic individuals and the degree of 
hypoadiponectinemia is highly correlated to the degree of insulin resistance and 
hyperinsulinemia (Hotta et al. 2000; Weyer et al. 2001). Another study showed that 
when given purified recombinant adiponectin treatment to normal and diabetic mice, 
serum glucose reduced without stimulating insulin was found in the diabetic mice 
which suggests that adiponectin is a potent insulin sensitivity enhancer (Berg et al. 
2001). In addition, growing evidence appears to support that adiponectin is involved 
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in the regulation of lipid metabolism. Decreased adiponectin levels have been linked 
to smaller LDL size and high apoB and triacylglycerol levels in young men (Kazumi 
et al. 2002). Plasma adiponectin levels have also been found to be negatively 
associated with triacylglycerol levels and positively associated with plasma HDL and 
the relationships are independent of age and sex (Cnop et al. 2003).  
 
1.4 Liver enzymes / receptors in regulating plasma lipids 
1.4.1   3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) 
HMG-CoA reductase, found in the endoplasmic reticulum (ER) of the liver and 
other cells and synthesized on membrane-bound ribosome, is the rate-limiting enzyme 
in the mevalonate pathway which is vital for hepatic cholesterol biosynthesis 
(Goldstein and Brown. 2009). The activity of HMG-CoA reductase is regulated by 
end-product feedback which was demonstrated by its suppression in human 
fibroblasts in the presence of serum containing high concentration of cholesterol and 
notably increasing after removing serum from the medium (Brown et al. 1973). 
Moreover, this study also showed that only LDL, not HDL was effective in 
suppressing HMG-CoA reductase activity. The most important mechanism of 
suppressing the activity of HMG-CoA reductase by cholesterol involves an inhibition 
of the transcription of a reductase gene. Stimulation of the degradation of pre-existing 
reductase protein is considered to be the second mechanism (Goldstein and Brown. 
1984). 
There are two forms of HMG-CoA reductase: phosphorylated (inactive) and 
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dephosphorylated (active). However, a study carried by Brown et al. (Brown et al. 
1979) elucidated that long term alteration of cholesterol synthesis in the rat liver is not 
due to the changes in the state of phosphorylation of reductase, but due to changes in 
the total amount of the protein. Because of the alteration effect of cholesterol 
synthesis, HMG-CoA reductase inhibitors such as lovastatin and related compounds 
have been found to reduce plasma cholesterol levels without serious side effects 
(Frishman and Rapier. 1989; Todd and Goa. 1990; Jungnickel et al. 1992). Nowadays 
these agents are widely used clinically as a well-known class of hypolipidemic drugs 
called “statins” (Goodman & Gilman's The Pharmacological Basis of Therapeutics, 
12e, chapter 31). 
 
1.4.2   Low density lipoprotein receptor (LDLR) 
LDLR was first found by Goldstein and Brown in 1973 through the research in a 
human genetic disease called familial hypercholesterolemia (Goldstein and Brown. 
2009; Brown and Goldstein. 1976) and they were awarded the Nobel Prize in 
physiology or medicine for their discoveries concerning “ the regulation of cholesterol 
metabolism” in 1985 (Hulsmann. 1986). LDLR is first synthesized in the rough ER as 
a precursor containing at least two high-mannose N-linked oligosaccharide chains, 
then converted to the complex N-linked chains to become a mature receptor in the 
Golgi (Goldstein and Brown. 1984). 
Receptor-bound LDL transports from the cell surface to the lysosome by 
endocytosis which facilitates the following rapid internalization and degradation (Fig 
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1-4) (Anderson et al. 1977). After internalization, the receptors dissociate from their 
ligands, run back to the cell surface and therefore being recycled. Usually, the time for 
LDLR going in and out of the cell once is 10 minutes and the lifespan of each 
receptor is around 20 hours (Brown et al. 1983). 
Together with HMG-CoA reductase, LDLR was also subject to the end-product 
feedback regulation by cholesterol (Fig 1-4) and they showed coordinate regulation in 
both in vitro and in vivo studies (Rudling. 1992; Goldstein and Brown. 1990). The 
balance between de novo cholesterol synthesis with HMG-CoA reductase as the 
rate-limiting enzyme and external cholesterol supply through the LDL receptor 
mediated endocytosis is important to stay away from intracellular sterol 
over-accumulation and elevation of plasma LDL levels (Goldstein and Brown. 1984; 
Goldstein and Brown. 1990). According to the most recent review by Goldstein and 
Brown (Goldstein and Brown. 2009), LDL derived cholesterol acts at different levels, 
including suppression of HMG-CoA reductase and LDLR gene expression through 
the sterol regulatory element-binding protein (SREBP) pathway which will be 
discussed later; acceleration of the degradation of pre-existing HMG-CoA reductase 
protein and activation of acyl CoA: cholesterol acyltransferase (ACAT) to esterify 
excess cholesterol to cholesteryl ester droplets which could be stored in the 
cytoplasm. 
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Figure 1-4. Sequential Steps in low density lipoprotein (LDL) receptor pathway. 
(Goldstein and Brown. 2009). ACAT, Acyl coenzyme A: cholesterol acyltransferase; 
HMG CoA reductase, 3-hydroxy-3-methylglutaryl coenzyme A reductase. Copyright 
permission has been granted. 
 
1.4.3 Sterol regulatory element-binding proteins (SREBPs) 
SREBPs belong to the basic helix-loop-helix-leucine zipper (bHLH-Zip) family of 
transcription factors and include three isoforms named SREBP-1a, SREBP-1c and 
SREBP-2 (Horton et al. 2002). Unlike other family members, SREBPs are 
synthesized as membrane-bound inactive precursors that require cleavage through a 
two-step proteolytic reaction which facilitates the entry of SREBP into the nucleus 
and activation of the genes for both cholesterol and fatty acid synthesis (Brown and 
Goldstein. 1997; Shimano. 2001). SREBP cleavage-activating protein (SCAP) is 
required to activate SREBP cleavage and is suggested to act as a sterol sensor in the 
liver (Korn et al. 1998). 
From the studies of transgenic mice overproducing SREBP-2 (TgSREBP-2), 
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Horton et al. (Horton et al. 1998) found that SREBP-2 is a relatively selective 
activator of cholesterol synthesis. Likewise, SREBP-1c was reported to be more 
selective in activating fatty acid synthesis, and over-expression of nuclear SREBP-1a 
activated both cholesterol and fatty acid synthetic genes (Shimano. 2001). mRNA 
expression of SREBP-1a and SREBP-1c was different in organs and cultured cells 
(Shimano et al. 1997). To be specific, SREBP-1a and SREBP-2 are predominantly 
expressed in most cultured cell lines while SREBP-1c and SREBP-2 are 
predominantly expressed in the liver and other tissues such as adipose tissue and the 
brain (Horton et al. 2002). 
Expression of SREBPs is also regulated by sterols (Fig 1-5). This has been 
confirmed by a number of lines of evidence. For example, cholesterol feeding reduced 
both nuclear SREBP-1c and SREBP-2 as well as LDL receptor protein levels in 
hamster liver (Shimomura et al. 1997) while deletion of sterols by administration of a 
bile acid-binding resin (colestipol) and a cholesterol synthesis inhibitor (mevinolin) 
led to an increase of nuclear SREBP-2 and a decline in the nuclear SREBP-1 in 
hamster liver (Shimomura et al. 1997; Sheng et al. 1995). Thirty-three genes involved 
in the synthesis of fatty acids and cholesterol were found to be increased in both 
transgenic mice overproducing SREBP-1a (TgSREBP-1a) and SREBP-2 
(TgSREBP-2) and to be decreased in SCAP-deficient mice (Horton et al. 2003). 
HMG-CoA reductase and LDL receptor are among these 33 genes and they showed a 
38 fold and 3.5 fold increases in mRNA levels in TgSREBP-2 liver, respectively. 
In Shimano‟s review (Shimano. 2001), he also summarized the effects of insulin 
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and glucose on SREBP-1 expression. SREBP-1c is up-regulated by insulin mainly in 
hepatocytes, and there is an increased possibility that the induction of SREBP-1c 
could mediate the roles of glucose and insulin in the production of fatty acids. 
 
 
Figure 1-5. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase, the rate limiting enzyme in cholesterol synthesis, and low density 
lipoprotein (LDL) receptor by sterols. A reduced availability of sterols causes the 
translocation of sterol regulatory element binding proteins (SREBPs) to the nucleus 
where they induce transcription of several genes involved in lipid metabolism, 
including up regulation of HMG-CoA reductase and LDL receptor. An increase in 
cell sterols has the opposite effect. 
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1.4.4   Microsomal triacylglycerol transfer protein (MTP) 
MTP, capable of accelerating the transfer of triacylglycerols and cholesteryl esters 
within the lumen of microsomes, was isolated from the liver and intestinal mucosa, 
and was first discovered and purified by Wetterau and Zilversmit (Wetterau and 
Zilversmit. 1984; Wetterau and Zilversmit. 1985; Wetterau et al. 1991b). Two bands 
of MTP protein were later recognized as two non-covalently bound polypeptides with 
the molecular weight 58 kDa and 97 kDa. (Wetterau and Zilversmit. 1985; Wetterau et 
al. 1991b; Wetterau et al. 1990; Wetterau et al. 1991a). The small 58 kDa subunit of 
MTP, which was identified as protein disulfide isomerase (PDI) later, is a ubiquitous 
multifunctional protein within the lumen of ER and not essential for the lipid transfer 
activity (Wetterau et al. 1991a; Wetterau et al. 1997). Unlike PDI, the large 97 kDa 
subunit is unique and is essential for MTP lipid transfer activity (Lamberg et al. 1996; 
Hussain et al. 2003a; Hussain et al. 2003b). 
The absence of functional MTP, caused by a defect in the gene for the large subunit 
of MTP was found in individuals with abetalipoproteinemia and it suggests that MTP 
is required for the assembly and secretion of lipoprotein containing apoB (Wetterau et 
al. 1992; Sharp et al. 1993). Jamil et al. (Jamil et al. 1995) summarized a 
well-accepted scheme of lipoprotein assembly and secretion in which initial assembly 
occurs in the ER. Apolipoptoteins, cholesterol, phospholipid and triacylglycerol are 
synthesized and incorporated into lipoprotein particles there, and then transported to 
the Golgi and secreted. MTP was proposed to carry the lipids from their synthesis site 
to nascent lipoproteins within the ER and has a preference for transporting neutral 
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lipids compared with phospholipids (Jamil et al. 1995).  
More studies have been done by different groups to demonstrate the role of MTP in 
the assembly and secretion of lipoproteins. Through different types of studies, 
Hussain et al. (Hussain et al. 2003b) suggested that apoB-MTP binding plays a role in 
lipoprotein biogenesis and may be important for the prevention of degradation and 
lipidation of nascent apoB. Hui et al. (Hui et al. 2002) demonstrated that the inability 
to express MTP was associated with a complete block in the secretion of both 
apoB-100 and apoB-48 without affecting triacylglycerol secretion in L35 rat 
hepatoma cell. Jamil et al. (Jamil et al. 1996) reported that an inhibitor of the MTP 
inhibits apoB secretion from HepG2 cells. Leung et al. (Leung et al. 2000) found that 
heterozygous MTP knockout mice with half-normal MTP levels in the liver reduce 
apoB secretion. Moreover, Tietge et al. (Tietge et al. 1999) provided the original data 
that hepatic over-expression of MTP resulted in increased secretion of 
VLDL-triacylglycerols as well as VLDL-apoB in vivo and also suggest that MTP is a 
rate-limiting enzyme for VLDL-apoB secretion in wild-type mice under basal 
chow-fed conditions. 
Insulin seems to be an important factor involved in MTP regulation. High insulin 
levels and high concentrations of glucose were found to decrease MTP large subunit 
mRNA levels in HepG2 cells (Lin et al. 1995). In the study of fructose-fed Syrian 
golden hamster, a novel animal model of insulin resistance, hepatic apoB 
overproduction was found and seems to result from increased intracellular stability of 
nascent apoB and elevation of MTP expression (Taghibiglou et al. 2000). 
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Figure 1-6. Role of hepatic microsomal triacylglycerol transfer protein (MTP) in 
the regulation apoprotein (apo) B-100 lipoproteins assembly. TG, triacylglycerols. 
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1.5 Methylglyoxal  
1.5.1 Synthesis of MG 
Methylglyoxal (MG) research started probably in the last decades of the 19th 
century and the research focus was the synthesis, the chemical characterization and 
reaction of MG (Kalapos. 1999). MG, also known as pyruvaldehyde, is a highly 
reactive aldehyde compound with two carbonyl groups (Fig 1-7) and is a yellow 
liquid with characteristic pungent odor. 
 
M.W=72.06 
Figure 1-7. Structure of methylglyoxal  
 
MG production has been discovered in all mammalian cells and it is mainly 
generated from the glucose metabolism via the glycolytic pathway (Phillips and 
Thornalley. 1993). In this pathway, the majority of MG is thought to be formed by the 
non-enzymatic and / or enzymatic elimination of phosphate from dihydroxyacetone 
phosphate (DHAP) and glyceraldehyde 3-phosphate (G-3-P). Triose phosphate 
isomerase or methylglyoxal synthetase may be involved in the enzymatic formation. 
Other important precursors for MG production include aminoacetone and ketone 
C
C
O
OH3C
H
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bodies derived from protein and triacylglycerol, respectively (Desai et al. 2010). 
Aminoacetone is a product of glycine and threonine metabolism and the conversion of 
aminoacetone into MG is catalyzed by semicarbazide-sensitive amine oxidase (SSAO) 
(Yu et al. 2003). The conversion of acetone into MG goes through two consecutive 
steps with acetol as an intermediate. Acetol/acetone monooxygenase (AMO) is the 
enzyme to convert acetol/acetone to MG production and this conversion consumes 
NADPH+H
+
 (Koop and Casazza. 1985).  
Moreover, over-consumption of high carbohydrates and fat food and/or high 
ethanol level beverages leads to elevated precursors for MG generation and the 
resultant overproduction of MG in vivo (Wu. 2006). 
 
1.5.2  Degradation of MG  
MG is a highly reactive compound and has been proved cytotoxic by both in vivo 
and in vitro studies (Kalapos. 1999).In healthy bodies, there are several mechanisms 
for MG detoxification and the glyoxalase system is known as a highly effective one 
(Kuhla et al. 2005) .  
The glyoxalase system, present in the cytosol of cells and cellular organelles, 
especially mitochondria, catalyses the conversion of MG to D-lactic acid with the 
help of two enzymes, glyoxalase I and glyoxalase II (Thornalley. 1990). Glyoxalase I 
catalyses hemithioacetal formed non-enzymatically from the reaction of MG and 
reduced glutathione (GSH) to S, D-lactoyl glutathione. Glyoxalase II hydrolyses S, 
D-lactoyl glutathione to D-lactic acid and regenerates GSH back to the detoxification 
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system. 
 
 
 
Figure 1-8. Synthesis and degradation of methylglyoxal. (Source: Desai et al., 
2010). Copyright permission has been granted. 
 
1.5.3 MG and reactive oxygen species (ROS) 
ROS is the term indicating free radicals derived from oxygen, such as superoxide 
(O2
•–
), hydroxyl radical (OH
•
), hydrogen peroxide (H2O2) and peroxynitrite (ONOO
–
). 
An excess of ROS production leads to an imbalance with antioxidants and therefore 
generates oxidative stress. Oxidative stress is the major inducer of the aging process 
and thus plays a role in many age-related diseases such as CVD and 
neurodegenerative diseases (Desai et al. 2010).  
Elevated ROS production by MG has been reported in numerous studies. 
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Incubation of rat aorta vascular smooth muscle cells (VMSCs) with MG for 4 hours 
significantly increased the production of superoxide in a dose dependent manner, 
which was attenuated by SOD (a superoxide scavenger) or diphenyleneiodonium (DPI, 
a NAD(P)H oxidase inhibitor) (Chang et al. 2005). Increased production of hydrogen 
peroxide and peroxynitrite, which is formed by an excess of superoxide reacting with 
nitric oxide, have also been found in the same study (Chang et al. 2005). Moreover, 
Over-generation of ROS was also found in other types of cells with incubation of MG, 
such as neutrophils (Ward and McLeish. 2004), monocytes (Rondeau et al. 2008) and 
rat hepatocytes (Kalapos et al. 1993). 
As mentioned above, MG is mainly degraded by the glyoxalase system whose 
activity is dependent on the GSH levels. Studies have shown that MG depleted GSH 
levels, which made the cells more sensitive to oxidative stress (Meister. 1988; Shinpo 
et al. 2000). Moreover, MG has been shown to inactivate glutathione peroxidase as 
well as glutathione reductase, which are the key enzymes to remove hydrogen 
peroxide and recycle GSH (Park et al. 2003; Blakytny and Harding. 1992). 
MG derived advanced glycation endproducts (AGEs) are another source for 
oxidative stress production, which has been found in various cells including 
endothelial cells (Thornalley. 1998; Wautier et al. 2001). Moreover, cytokines and 
growth factors such as interleukin 1 beta were proposed to act as mediators for the 
indirect cause of ROS elevation by MG (Lo et al. 1994; Oya et al. 1999; Westwood 
and Thornalley. 1996). 
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1.5.4 MG and AGEs 
  AGEs, a group of brown colored compounds with intra- or inter-molecular cross 
linking, are formed by the Maillard reaction of aldehydes and ketones with amino 
groups of proteins (Singh et al. 2001). The formation of AGEs is age-correlated (Li et 
al. 1996) and they are found to accumulate slowly in vascular and renal tissues. 
However, the accumulation of AGEs is accelerated in conditions such as 
complications of diabetes (Brownlee et al. 1988). 
  As the most active AGE precursor, MG reacts with residues of different proteins 
including arginine, lysine and cysteine and therefore forms different AGEs, such as 
argpyrimidine, N

-caboxyethyl lysine (CEL) and N

-carboxymethyl lysine (CML) 
(Dhar et al. 2008).  
Numerous studies, both in vivo and in vitro have proved that increased MG leads to 
an increase of AGEs formation. In cultured VSMCs, CEL and CML production 
detected by using immunohistochemistry increased significantly after treatment with 
MG for 3 hours (Dhar et al. 2008). In the spontaneously hypertensive rat (SHR) 
kidney, immunoreactivity to CEL and CML increased at 8, 13 and 20 weeks groups 
compared to age-matched Wistar-Kyoto (WKY) rats, but not in the 5 week group, 
following the same pattern as MG levels in the plasma (Wang et al. 2004; Wang et al. 
2005). 
  
1.5.5 Role of MG in diabetes  
  Clinical data has shown that plasma MG concentrations are 5-6 fold higher in 
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patients with Type 1 diabetes mellitus and 2-3 fold in those with type 2 diabetes 
mellitus (McLellan et al. 1994). 
In vitro studies showed that in cultured VSMCs and endothelial cells, MG 
increased significantly after high concentration of glucose (25 mM) treatment (Dhar 
et al. 2008; Dhar et al. 2010b). The increased AGEs associated with increased MG 
under hyperglycemia have been suggested as a causative factor for diabetes mellitus 
and its complications (Wang et al. 2007).  
  Argpyrimidine, one of the AGEs formed by MG and arginine residue, has been 
found to accumulate in atherosclerotic lesions in diabetic patients and has a positive 
correlation with the severity of atherosclerotic lesions (Oya et al. 1999; Friedman. 
1999). Moreover, AGEs can up-regulate vascular cell adhesion molecule-1 (VCAM-1) 
expression through activation of NF-κB signaling pathway and therefore trigger the 
first step of atherogenesis (Kunt et al. 1999). 
 Similarly, elevated AGEs have also been demonstrated to be localized in the 
kidney and retinal blood vessels in diabetic mice or patients, and these abnormalities 
have been linked to diabetic nephropathy and diabetic retinopathy, respectively 
(Soulis-Liparota et al. 1995; Stitt. 2001). 
 
  1.5.6 Role of MG in hypertension  
Compared to the role of MG and AGEs in diabetes mellitus, their role, if any, in the 
pathogenesis of hypertension has not been well studied, especially under 
normoglycemic condition (Wang et al. 2007). 
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Data in our lab showed that cellular MG levels and MG-induced AGEs levels in 
cultured rat aorta VMSCs from SHR were significantly higher than those from 
normotensive WKY rats. The systolic blood pressure was also found to be 
significantly higher in SHR 8 weeks and older, but not at 5 weeks, and this 
age-dependent increase coincided with the increase in MG levels in both the aorta and 
the plasma of SHR. Aminoguanidine, an MG and AGEs scavenger, attenuated the 
increase of systolic blood pressure accompanied by an attenuation of the increases of 
MG and AGEs levels (Wang et al. 2007; Wang et al. 2005). 
MG also targeted the kidney which is a key organ for regulating the blood 
pressure. Kidney MG levels were found to be significantly higher in 13 and 20 week 
old SHR compared to age-matched WKY rats. Kidney AGEs formation also increased 
significantly in SHR 8 weeks and older. The majority of the AGEs were localized in 
renal tubules with a small amount in the glomerular vessels. Moreover, GSH levels in 
the kidney also decreased in SHR at 20 weeks (Wang et al. 2004). 
In addition, MG-induced ROS may be another causative factor for hypertension. 
Increased production of superoxide impairs nitric oxide function and leads to blood 
vessel tone alteration while increased formation of peroxynitrite leads to endothelial 
cell dysfunction and therefore results in hypertension (Cuzzocrea et al. 2004). ROS 
also plays a role in NF-κB activation which is essential for VSMC proliferation 
during the hypertension development (Wu. 2006). 
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1.5.7 Previous findings in MG treated rats 
Acute and chronic administration of MG has been performed separately in SD rats 
to investigate the direct effects of MG. In the acute study (Dhar et al. 2010a), a single 
dose of 17.25 mg/kg MG was given to one group of rats by intraperitoneal 
administration. Two other groups included a control group and a group pre-treated 
with alagebrium (ALA), a MG scavenger and an AGEs breaker. MG levels in 
different tissues and urine were measured by HPLC and a significant increase of the 
MG levels was found in the different tissues including heart, kidney, liver, lung, aorta 
and urine and the changes were attenuated by ALA (Fig 1-9). Plasma glucose and 
insulin levels were significantly increased after acute MG administration and glucose 
uptake was reduced compared to the control groups.  
 
 
 
Figure 1-9. Distribution of methylglyoxal (MG) in different organs/tissues/urine 
in Sprague-Dawley rats after intraperitoneal administration. Saline (control), MG 
(17.25 mg/kg i.p., MG-17 i.p.) or MG-17 i.p. + ALA (alagebrium 100 mg/kg i.p.) 
were administered to three groups of rats (n = 6 each). The organs, tissues and urine 
were collected 3 h after administration of treatment. Data were analyzed with 
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two-way ANOVA with treatment and tissue as variables. *P<0.05, **P<0.01, 
***P<0.001 vs. corresponding control group, 
†
P<0.05, 
††
P<0.01 vs. MG-17 i.p. group. 
(Source: Dhar et al. 2010a). Copyright permission has been granted. 
 
   In the chronic study, an osmotically driven infusion minipump was implanted 
subcutaneously in the back of the rat to deliver 60 mg/kg/day of MG by continuous 
infusion for 28 days (Dhar et al. 2011). MG levels in the plasma, pancreas, adipose 
tissue and skeletal muscle increased significantly after chronic MG treatment and this 
increase was exacerbated by glutathione synthesis inhibitor, L-buthionine sulfoximine 
(BSO) and attenuated by the MG scavenger and AGEs breaker, ALA. In contrast, 
GSH levels in these tissues were decreased after chronic MG treatment (Fig 1-10). 
Basal plasma glucose levels were significantly elevated, basal plasma insulin levels 
were decreased with impaired glucose tolerance and glucose uptake in the MG treated 
group. In this chronic study, plasma lipid profile of rats in different groups was also 
evaluated (Table 1-4). Significantly elevated plasma free fatty acids, total cholesterol, 
and triacylglycerols as well as decreased HDL levels were found after MG treatment. 
Co-treatment with ALA attenuated the alterations of plasma lipid levels induced by 
chronic MG treatment. The reason for the changes in lipid levels was not pursued in 
that study. I undertook this exciting project to investigate the mechanisms of these 
MG-induced changes in plasma lipid levels. 
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Parameter 
 
Control MG MG+ALA ALA 
Plasma free 
fatty acids 
(μg/L) 
393±41 619±21*** 405±20
†††
  389±22
†††
 
Total 
Cholesterol 
(mmol/L) 
1.8±0.1 2.4±0.05*** 1.9±0.03
††
 - 
HDL (mmol/L) 1.2±0.05 0.7±0.06** 1.0±0.07
†
 - 
Triacylglycerols 
(mmol/L) 
0.2±0.03 0.5±0.04*** 0.3±0.02
††
 - 
 
Table 1-4. Plasma lipid levels in Sprague-Dawley rats treated with methylglyoxal 
(MG). 0.9% saline or MG (60 mg/kg/day) was delivered by continuous infusion with 
a subcutaneous osmotic pump for 28 days to all groups of rats (n=6 each). The MG 
scavenger, alagebrium (ALA, 30 mg/kg/day in drinking water) (MG+ALA and ALA) 
was administered to some groups of rats. The control group received only saline (0.9% 
by pump). After 28 days basal fasting plasma levels of substances listed in the table 
were measured.  The values are Mean ± SEM of n = 6 experiments. **P<0.01, 
***P<0.001 vs respective control group; 
†
P<0.05, 
††
P<0.01, 
†††
P<0.001 vs respective 
MG group. 
Abbreviations: HDL, high density lipoprotein. (Source: Dhar et al., 2011). Copyright 
permission has been granted. 
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Figure 1-10. Methylglyoxal (MG) levels are elevated and reduced glutathione 
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(GSH) levels are decreased in Sprague-Dawley rats chronically treated with MG. 
0.9% saline or MG (60 mg/kg/day) was delivered by continuous infusion with a 
subcutaneous osmotic minipump for 28 days to all groups of rats (n=6 each). The MG 
scavenger, alagebrium (ALA, 30 mg/kg/day in drinking water) (MG+ALA) or 
glutathione synthesis inhibitor, L-buthionine sulfoximine (BSO, 30 mg/kg/day in 
drinking water) (MG+BSO and BSO) were administered to some groups of rats. The 
control group received only saline (0.9% by pump). After 28 days MG and GSH 
levels were determined by HPLC in (A, E) plasma and (B-D, F-H) organs. *P<0.05, 
**P<0.01, ***P<0.001 vs respective control, 
†
P<0.05, 
††
P<0.01, 
†††
P< 0.001 vs 
respective MG group, 
‡
P<0.05, 
‡‡
P<0.01, 
‡‡‡
P<0.001 vs. respective MG+BSO group. 
(Source: Dhar et al., 2011). Copyright permission has been granted. 
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1.6  Hypothesis 
We hypothesized that MG contributes to the pathogenesis of dyslipidemia by 
affecting one or more of the factors responsible for triacylglycerol and fatty acids 
metabolism/transport and storage in the adipose tissue and/or key enzymes involved 
in cholesterol and lipoprotein metabolism/transport in the liver. 
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1.7  Objectives 
The objectives of this study are to investigate the effects of MG on lipid regulation 
in both the adipose tissue and cultured adipocytes, then further assess the potential 
role of C/EBPs, PPARγ, TNFα, lipoprotein lipase and adipokines related to 
MG-induced plasma lipid level alterations. In addition, we also investigated the 
effects of MG on several key enzymes/receptors related to cholesterol and lipoprotein 
metabolism/transport in the liver. 
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1.8 Research Protocol Outline 
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CHAPTER TWO 
MATERIALS AND METHODS 
2.1 Animal treatment 
Male SD rats, 12 weeks old, were purchased from Charles River Laboratories 
(St-Constant, Quebec, Canada). Rats were treated according to guidelines of the 
Canadian Council on Animal Care and all animal protocols were approved by the 
Animal Care Committee of the University of Saskatchewan. SD rats were randomly 
divided into four groups (n=6 each): (i) Control (0.9% saline), (ii) MG treated, (iii) 
MG+aminoguanidine (AG) treated. MG (60 mg/kg/day) or 0.9% saline was delivered 
by continuous infusion with a subcutaneously implanted minipump for 4 weeks. AG 
(100 mg/kg/day) was delivered in drinking water for 4 weeks. After 4 weeks of the 
treatment, the rats were anesthetized with thiopental sodium (100 mg/kg i.p.) and 
sacrificed by exsanguination. Blood was collected from the heart and plasma was 
separated by centrifuging the blood samples at 1000 rpm for 10 minutes at 4°C. The 
liver and adipose tissue were isolated and rinsed in cold saline, frozen in liquid 
nitrogen and stored at -70 °C. The liver and adipose tissue were finely ground in 
liquid nitrogen before performing different assays. 
 
2.2  3T3-L1 cell culture and differentiation 
Mouse 3T3-L1 cell line was purchased from American Type Culture Collection 
(ATTC) and grown to confluence in Dulbecco‟s Modified Eagle‟s Medium (DMEM) 
(Sigma, MO, USA) containing 1% penicillin-streptomycin, 25 mM glucose and 10% 
heat inactivated bovine serum (Invitrogen, CA, USA). One day after confluence (Day 
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0), cell differentiation was induced by adding 1.0 µg/mL insulin, 0.25 mM 
dexamethasone, and 0.5 mM isobutylmethylxanthine to the medium (DMEM 
containing 25 mM glucose and 10% heat inactivated fetal bovine serum(FBS) (PAA 
Laboratories, Ontario, Canada) for 3 days and the medium was changed every day. 
The cells then grew in post-differentiation medium (DMEM containing 25 mM 
glucose, 10% FBS and 1.0 µg/mL insulin) for 4-6 days and the medium was changed 
every other day until more than 90% of cells became mature adipocytes. For 
determination of the effects of MG on mature adipocytes, after 18 hours starvation, 
3T3-L1 cells were placed in DMEM (containing 5mM glucose and 10% FBS) and 
treated with or without MG (30 µM) for 24 h. In oil-red O staining, cells were given 
treatment from day 0 for 6-8 days until the adipocytes became mature. All the other 
chemicals were purchased from Sigma. 
 
2.3 Hematoxylin-eosin staining (H-E staining) 
Abdominal adipose tissue was collected from rats and kept in buffered 10% 
formalin solution at 4 ºC after rinsing with cold phosphate buffered saline (PBS). A 
small piece of adipose tissue was embedded in paraffin through a series of processes 
run by RVG/1 vacuum tissue processor (Belair, NJ, USA). After embedding, each 
piece was held in a steel embedding ring. After trimming and sectioning (5 µM each 
section) by using „A20‟ microtome (Spencer, NH, USA), the tissue sections were 
finally attached to the slides and ready for staining after overnight drying at 37 ºC. For 
staining, the slides were deparaffinized in xylene, stained with hematoxylin for 3 
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minutes and eosin for 1 minute, mounted and examined by light microscopy. For each 
abdominal adipose tissue sample, 3 sections were prepared. Photographs were taken 
from 4 random areas per section at 20× magnification. The number of adipocytes per 
area (0.0221 mm
2
) was counted and the mean value of each sample was calculated 
upon the number of 4 random areas per section.  Mean adipocyte density and 
adipocyte size was then calculated upon the number per mm
2
. 
 
2.4  Oil-Red O staining 
For Oil-Red O staining, cells were gently washed 2 times with PBS, fixed with 10% 
formalin for at least 1 hour at room temperature and stained with filtered Oil Red O 
working solution for 10 minutes. After intracellular lipid droplets were fully stained, 
the Oil Red O solution was removed and cells were rinsed with tap water. Images 
were taken under a microscope after drying the cells. At last, the dye was eluted by 
adding 100% isopropanol for 10 minutes and quantified by measuring the optical 
absorbance at 500 nm (Ramirez-Zacarias et al. 1992) by using a plate reader (Thermo 
Labsystems, Finland). 
 
2.5  Protein extraction 
The cultured cells were washed with cold PBS for 2 times, then scrapped and 
collected in centrifuge tubes. After 1000 rpm, 5 minutes centrifugation, the 
supernatant was discarded and the pellet was resuspended in 200 µL lysis buffer (100 
volumes of 1×RIPA buffer with 1 volume of 100 mM phenylmethysulfonyl fluoride 
and 1 volume of protease inhibitor) for 1 hour. After centrifugation at 12000 rpm for 
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10 minutes, the supernatant was transferred to another eppendorf tube for protein 
determination. For the tissue protein extraction, a certain amount of fine tissue powder 
(adipose tissue 100-120 mg, liver 40-50 mg) was weighed and immediately 300 µL of 
lysis buffer was added into the tube containing the tissue powder. After sonication at 
40% power for 15 seconds (5 seconds on, 10 seconds off, 3 times), the tube was left 
on ice for 30 minutes. Centrifugation and supernatant collection was the same as those 
for cells. 
 
2.6  Nuclear protein extraction 
Triton X-100 lysis buffer was prepared according to online protocol <western blot 
analysis of sub-cellular fractionated samples using the Odyssey infrared Imaging 
System> and added to 100-150 mg of liver sample with a volume of 500 µL each. 
After lysis on ice for 30 minutes and centrifugation (13000 rpm, 4° C, 10 minutes), 
nuclear and cytosol fractions of the samples were separated. The cytosol part, which 
formed the supernatant, was discarded, while the nuclear part, which formed the 
precipitate, was rinsed with the same lysis buffer for 2 times by high speed 
centrifugation (13000 rpm, 4° C, 5 minutes each). The nuclear fraction was 
resuspended in 200 µL lysis buffer containing 0.5% SDS and sonicated (5 seconds, 3 
times). Nuclear protein was collected from the supernatant after the fourth 
centrifugation and used for protein determination before western blotting. 
 
2.7  Determination of protein concentration 
The protein concentrations of cell or tissue samples were determined by BCA 
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(bicinchoninate) assay (Ramirez-Zacarias et al. 1992). 10 µL BSA ranging from 
0.3125 to 5 mg/mL were used as standards and the same amount of double distilled 
water or supernatant were added in the plates as blank or samples, respectively. After 
30 minutes incubation with 200 µL 50 volumes of bicinchoninic acid solution and 1 
volume of copper (II) sulfate solution (Sigma-Aldrich Corp., St. Louis, MO, USA) at 
37 °C, the spectrophotometric absorbance of samples was determined using a plate 
reader (Thermo Scientific, Vantaa, Finland) at 562 nm. The values of samples were 
calculated according to the standard curve. 
 
2.8  Western blotting 
Cell lysate was separated by 8% or 10% SDS-PAGE, electrotransfered onto a 
polyvinylidene fluoride membrane, blocked with 5% skim milk for 30 minutes and 
incubated with primary antibodies diluted in skim milk overnight at 4º C. The next 
day, after 2 hours of thorough washing with PBST buffer (PBS with 0.1% tween-20), 
the membranes were incubated with horseradish peroxidase-conjugated secondary 
antibodies for 2 hours at room temperature. After 1 hour washing, the immunoreactive 
proteins were detected with an Enhanced Chemiluminescence Detection System. 
Primary antibodies for adiponectin were purchased from Cell Signaling Technology, 
Inc. (Danvers, MA, USA), C/EBPα was purchased from Abcam (Cambridge, MA, 
USA), β-actin was purchased from Sigma (Sigma-Aldrich Corp., St. Louis, MO, 
USA), and secondary anti-rabbit and anti-mouse lgG antibodies were from Cell 
Signaling while other antibodies were from Santa-Cruz (Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA, USA). 
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2.9  Real-time quantitative polymerase chain reaction (RT-PCR)  
Total cellular RNA of 3T3-L1 cells and liver tissue was extracted by using RNeasy 
mini kit (Qiagen, Valencia, CA, USA) and total cellular RNA of adipose tissue was 
extracted by using RNeasy lipid tissue mini kit (Qiagen, Valencia, CA, USA) 
according to the manufacturer‟s instructions. Total RNA (1 µg) was 
reverse-transcribed to single-stranded cDNA by using iScript
TM
 cDNA synthesis kit 
(Bio-Rad Laboratories, Hercules, CA, USA) after reaction for 5 minutes at 25º C, 30 
minutes at 42º C, 5 minutes at 85º C and held at 4º C in iCycler iQ apparatus 
(Bio-Rad Laboratories, Hercules, CA, USA) associated with the iCycler optical 
system software (version 3.1). The target cDNAs mixed with primers (Qiagen, 
Valencia, CA, USA) and SYBR Green (Bio-rad Laboratories, Hercules, CA, USA) 
were triplicated and run for 45 cycles at 95º C for 30 seconds, 55º C for 1 minutes and 
72º C for 30 seconds. 18s rRNA was applied as the internal standard. Crossing point 
(CP) (cycle threshold (Ct)) of each transcript was determined by iCycler 
automatically after the cycling and the result was calculated by a mathematical 
delta-delta method in which the equation is ratio=2
-(△CPsample-△CPcontrol) 
(Pfaffl. 2001). 
For each cycling, the effiency of amplification was between 90%-110%. 
 
2.10  Leptin assay  
Rat‟s plasma or 3T3-L1 culture medium were collected to determine leptin 
concentrations using Quantikine® mouse leptin kit (R&D Systems Inc., Minneapolis,  
MN, USA) based on an enzyme-linked immunosorbent assay. According to the 
manufacturer‟s instructions, the samples strictly avoided repeated thawing. 
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2.11  Data analysis and statistics 
Data are expressed as or Mean ± SEM from at least three independent experiments. 
ANOVA or Student‟s paired/unpaired t test was used for statistical analysis. P < 0.05 
was considered significant. 
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CHAPTER THREE 
RESULTS 
3.1  MG induced hypertrophy of adipocytes in rats 
As shown in Figure 3-1A, after 4 weeks of chronic MG treatment, the size of 
adipocytes from abdominal adipose tissue increased compared to that from control 
rats while AG co-treatment attenuated this increase (cytosol is stained pink by eosin 
and nuclei stained blue by hematoxylin, eosin also stained blood vessels). In Figure 
3-1B, the adipocyte number was counted in 4 random areas of each section, mean cell 
number per mm
2
 was calculated and it could quantitate the difference presented in 
figure 3-1A, but inversely. Cell size calculation was based upon the cell number per 
mm
2 
(Figure 3-1C). A significant decrease (P<0.001 vs. control rats) of density and 
increased cell size (P<0.05 vs. control rats) was found in chronic MG treated rats, 
which was attenuated by co-treatment with AG (P<0.05 vs. chronic MG treated rats).  
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A    
 
 
B                                      C  
 
Figure 3-1. Effects of methylglyoxal (MG) or MG co-treated with 
aminoguanidine (AG) on adipocytes size in rat abdominal adipose tissue. 
Hematoxylin-eosin staining was applied on paraffin embedded adipose tissue sections. 
Images are shown (A), and mean adipocytes number per mm
2
 was calculated (B), and 
cell size was obtained based on the cell number (C). *P<0.05, ***P<0.001 vs. control, 
#P<0.05 vs. chronic MG treated rats, n=3-5 for each group. 
 
 
 
 
  
Con MG MG+AG 
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3.2 MG increased TNFα mRNA expression without altering leptin and LPL 
mRNA expression in adipose tissue 
In cultured cells, the majority amount of leptin was found to be secreted into the 
medium while a small amount of leptin stays in the cells (MacDougald et al. 1995b). 
Therefore, mRNA expression of leptin was chosen rather than intracellular protein 
expression. LPL mRNA and TNFα mRNA expression were also measured by 
real-time PCR to detect the effects of MG on adipocyte lipid metabolism. In the 
adipose tissue which extracted from chronic MG treated rats, no significant difference 
was found in leptin and LPL mRNA expression while TNFα mRNA expression 
significantly increased by 85.1% when comparing to the ones extracted from control 
rats (*P<0.05 vs. control, Figure 3-2A). 
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Figure 3-2. Effects of methylglyoxal (MG) on mRNA expression of leptin, 
lipoprotein lipase (LPL) and tumor necrosis factor alpha (TNFα) in adipose 
tissue. Leptin, LPL and TNFα mRNA expression in adipose tissue from rats treated 
with MG was determined by real-time PCR and the results are presented as % of their 
corresponding controls (A). TNFα mRNA expression in adipose tissue from MG 
treated rats with or without co-treatment with AG was also measured (B). *P<0.05 vs. 
control, n=4-6 for each group. 
  
A B 
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3.3  MG increased C/EBPα, C/EBPβ protein levels in adipose tissue  
C/EBPα and C/EBPβ are the transcription factors for adipocyte differentiation and 
are necessary for adipocyte gene expression and lipid accumulation. To determine 
whether MG influences expression of these adipocyte differentiation factors, western 
blotting was applied on adipose tissue lysate from different groups. Protein levels of 
C/EBPα (Figure 3-3A) and C/EBPβ (Figure 3-3B) in chronic MG treated rats 
increased by 162.8% and 120.6%, respectively and the effect of MG was counteracted 
by AG co-treatment (Fig. 3.3B). 
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Figure 3-3. Effects of methylglyoxal (MG) or MG co-treated with 
aminoguanidine (AG) on the protein levels of CCAAT/enhancer binding protein   
(C/EBP)α and C/EBPβ in adipose tissue. Western blotting showing the protein 
levels of C/EBPα (A) and C/EBPβ (B) in adipose tissue from different groups of 
treated rats. Data analysis was based on the manual quantification of the western 
images by Genesnap software from Syngene. **P<0.01 vs. control, #P<0.05 vs. 
chronic MG treated rats, n=4-5 for each group. 
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3.4  MG did not change PPARγ protein levels significantly 
As an important factor involved in adipogenesis, insulin sensitivity and 
dyslipidemia in adipose tissue (Gurnell et al. 2003), PPARγ protein levels were 
examined by western blotting and found to be increased by 34.1%, but the difference 
was not significant (P=0.26) (Figure 3-4). 
 
 
Figure 3-4. Effect of methylglyoxal (MG) on the gene expression of peroxisome 
proliferator activated receptor gamma (PPARγ) in adipose tissue. Western 
blotting shows the two isoforms of PPARγ. Results were quantified and normalized 
after dividing by β-actin. n=5 for each group. 
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3.5  MG did not alter gene expression of adiponectin and LPL in adipose tissue  
Using western blotting, we also compared protein levels of another important 
adipokine, adiponectin ((Figure 3-5B) and LPL (Figure 3-5C) in adipose tissue from 
rats treated with or without MG. Both adiponectin and LPL did not show any change 
compared to the control group. 
 
   A                                 B 
 
Figure 3-5. Effects of methylglyoxal (MG) on the gene expression of adiponectin 
and lipoprotein lipase (LPL) in adipose tissue. Western blotting shows the protein 
levels of adiponectin (A) and LPL (B) in adipose tissue from rats treated with or 
without MG. n=5-6 for each group. 
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3.6  MG did not alter leptin levels in rat plasma 
Because no alteration was found in leptin mRNA levels in chronic MG treated rats, 
an enzyme-linked immunosorbent assay (ELISA) was further applied to rat plasma to 
determine circulating leptin levels. However, same as mRNA levels, no difference 
was found between the MG treated and untreated group. 
 
 
Figure 3-6. Effect of methylglyoxal (MG) on circulating leptin levels in rat 
plasma. Leptin levels of plasma collected from control rats and chronic MG treated 
rats were measured by a commercial ELISA kit. n=3 for each group. 
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3.7  MG increased lipid accumulation in cultured 3T3-L1 adipocytes 
To explore the adipogenesis potential of MG, we differentiated 3T3-L1 
pre-adipocyte with 10 µM and 30 µM of MG for 6 days (from day 0-6). Lipid 
accumulation was quantified by Oil-Red O staining. MG increased the optical density 
(OD) value of Oil-Red O eluted solution at higher concentration (Figure 3-6B) and 30 
µM MG exhibited a significantly higher OD value (P<0.001 vs. control) which 
indicated higher lipid accumulation in the cytoplasm. 
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Figure 3-7. Effects of methylglyoxal (MG) on lipid accumulation in 3T3-L1 
adipocytes. Cells were cultured in the medium in the absence or presence of MG 
from Day 0 to Day 6, and lipid accumulation was measured by Oil-Red O staining. (A) 
Oil-Red O staining images, n=6. (B) Effects of different concentrations of MG on 
quantitative Oil-Red O. (C) Effects of 30 µm MG on quantitative Oil-Red O. *P< 
0.05 with control, n=6 for each group. 
 
 
  
Con MG 30 μM 
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3.8  MG increased TNFα mRNA levels without altering leptin and LPL mRNA 
levels in 3T3-L1 adipocytes 
The mRNA levels of leptin, LPL and TNFα in cultured 3T3-L1 adipocytes were 
affected in a manner similar to the adipose tissue. Thus, leptin and LPL mRNA 
expression was not altered after 24 hours treatment with 30 µM exogenous MG while 
TNFα mRNA level was up-regulated by 89.3% (*P<0.05 vs. control). 
 
 
Figure 3-8. Effects of methylglyoxal (MG) on the expression of leptin, lipoprotein 
lipase (LPL) and tumor necrosis factor alpha (TNFα) in 3T3-L1 adipocytes. After 
24 hour treatment in the absence or presence of MG (30 µM) on mature adipocytes, 
the RNA extraction was carried out and further used for leptin, LPL and TNFα mRNA 
expression determination by real-time PCR. mRNA levels in MG treated 3T3-L1 
adipocytes are presented as % of their corresponding controls.* P<0.05 vs. control, 
n=4 for each group. 
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3.9  MG up-regulated C/EBPα and C/EBPβ gene expression in 3T3-L1 
adipocytes 
Expression of adipogenesis transcription factors C/EBPα and C/EBPβ were 
determined by western blotting in 3T3-L1 adipocyte lysates. After 24 hours, 
expression of C/EBPα and C/EBPβ in the MG treatment group increased significantly 
by 99.5% and 101.7% compared to control (**P<0.01 vs. control, Figure 3-9A and 
*P<0.05 vs. control, Figure 3-9B). 
 A                                 B                           
 
Figure 3-9. Effects of methylglyoxal (MG) or MG co-treated with 
aminoguanidine (AG) co-treatment on the protein levels of C/EBPα and C/EBPβ 
in 3T3-L1 adipocytes. After 24 hour treatment of mature 3T3-L1 cells in the absence 
or presence of MG (30 µM), the protein levels of  C/EBPα (A) and C/EBPβ (B) were 
determined by western blotting. *P<0.05 vs. control, **P<0.01 vs. control, n=4-5 for 
each group. 
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3.10  MG did not change PPARγ protein levels  
Protein levels of PPARγ in 3T3-L1 adipocytes were detected by western blotting 
and showed results similar to those in the adipose tissue. MG increased PPARγ 
protein levels by 15.3%, which was not significant. 
 
 
Figure 3-10. Effect of methylglyoxal (MG) on the gene expression of peroxisome 
proliferator activated receptor gamma (PPARγ) in 3T3-L1 adipocytes. After 24 h 
treatment with or without exogenous MG, whole cell lysate was used for western 
blotting and the expression of PPARγ was quantified. n=5-6 for each group. 
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3.11  MG did not alter adiponectin and LPL expression in 3T3-L1 adipocytes 
Same as what we found in adipose tissue, the expression of adiponectin and LPL 
was also measured in 3T3-L1 adipocytes by the same method. 4-5 samples were 
collected in each of MG treatment and control groups. After western blotting and 
quantification, 22.8% increase was found in adiponectin expression in the MG treated 
group, which was not significant (P=0.12, figure 3-9A). No significant difference was 
also observed in LPL expression.  
A                               B                     
 
Figure 3-11. Effects of methylglyoxal (MG) on the expression of adiponectin and 
lipoprotein lipase (LPL) in 3T3-L1 adipocytes. Western blotting showing the 
expression of adiponectin (A) and LPL (B) in 3T3-L1 adipocytes after 24 hour 
incubation with or without MG (30 µM). n=4-5 for each group. 
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3.12  MG did not alter leptin secretion in cultured adipocytes 
Cell culture medium was collected at the end of 24 hour treatment and assayed for 
leptin after centrifugation to eliminate any possible cell particles. 269.0 pg/ml was the 
mean value of leptin levels in the medium from both MG treated group and control 
group with 4 samples in each group. 
 
 
Figure 3-12. Methylglyoxal (MG) did not alter leptin secretion in 3T3-L1 
adipocytes. Cell culture medium was collected after 24 hour treatment in the absence 
or presence of MG (30 µM) and used for leptin ELISA assay. n=4 for each group. 
 
 
 
 
 
 
 
 
 
  
71 
 
3.13  MG up-regulated gene expression of SREBP-2 without affecting SREBP-1 
in the liver 
Liver is another important organ involved in lipid metabolism. SREBP-1, the 
activator which mainly enhances the gene transcription required for fatty acid 
synthesis but not cholesterol synthesis (Horton et al. 2002), changed negligibly in the 
liver of MG treated rats compared to the control rats (Figure 3-13A). SREBP-2, the 
activator for cholesterol synthesis, not fatty acids synthesis, increased significantly by 
119.0% (*P<0.05 vs. control, Figure 3-13B). 
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Figure 3-13. Effects of methylglyoxal (MG) on sterol regulatory element-binding 
protein (SREBP)-1 and SREBP-2 protein levels in the liver. 40 μg nuclear proteins 
extracted from liver samples were loaded in western gels and used for western 
blotting for SREBP-1 and SREBP-2. Lamin B was used as a nuclear protein marker 
here. Protein levels of SREBP-1 (A) and SREBP-2 (B) are presented after dividing by 
lamin B levels. *P<0.05 vs. control, n=4-5 for each group. 
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3.14 MG increased HMG-CoA reductase in the liver without affecting LDL 
receptor 
The level of LDL in plasma could be dictated by the balance between the 
HMG-CoA reductase and LDL receptor  and MG was found to significantly 
up-regulate HMG-CoA reductase by 47.5% (*P<0.05 vs. control, Figure 3-14B) 
without affecting both LDL-receptor mRNA (Fig3-14A) and protein levels (Fig 
3-14C). 
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Figure 3-14. Effects of methylglyoxal (MG) on 3-hydroxy-3-methylglutaryl 
conenzyme A reductase (HMGCR) and low density lipoprotein receptor (LDLR) 
protein / gene expression in the liver. LDLR mRNA levels (A) were measured by 
real-time PCR and protein levels of HMG-CoA reductase (B), and LDLR (C) was 
measured by applying western blotting on whole protein lysate. *P<0.05 vs. control, 
n=4 for each group. 
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3.15  MG increased MTP expression in the liver 
MTP is a rate-limiting protein for hepatic apoB secretion which is a major 
determinant of plasma triacylglycerols and LDL levels (Tietge et al. 1999). In the 
liver of chronic MG treated rats, the protein level of MTP increased significantly by 
79.7% and the effect was attenuated in MG+AG co-treated rats (*P<0.05 vs. control). 
            
 
Figure 3-15. Effects of methylglyoxal (MG) on microsomal triacylglycerol 
transfer protein (MTP) expression in the liver. Whole protein lysates from liver 
samples were used for examining MTP protein levels by western blotting. *P<0.05 vs. 
control, n=4 for each group. 
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3.16  Summary of results 
Parameter Chronic MG treated rats Cultured 3T3 cells MG(30 µM) 
 Adipose tissue Cultured cells 
Adipocyte  ↑ size, ↓ number  
Lipid accumulation  ↑ 
TNFα ↑ mRNA ↑ mRNA 
Leptin 
 
↔ mRNA 
↔ plasma level 
↔ mRNA 
↔ secretion 
LPL ↔ mRNA and protein ↔ mRNA and protein 
C/EBPα protein ↑ ↑ 
C/EBPβ protein ↑ ↑ 
PPARγ protein ↔ ↔ 
Adiponectin protein ↔ ↔ 
Plasma leptin ↔  
 Liver  
SREBP1 ↔ protein  
SREBP2 ↑ protein  
MTP ↑ protein  
LDL receptor ↔ protein  
HMG-CoA reductase ↑ protein  
 
Abbreviations and symbols: C/EBP, CCAAT- enhancer binding protein; HMG-CoA 
reductase, 3-hydroxy3-methyl glutaryl coenzyme A reductase; LPL, lipoprotein lipase; 
PPARγ, Peroxisome proliferator activated receptor γ; SREBP, Sterol regulatory 
element binding protein; TNFα, tumour necrosis factor α. 
↑ increase; ↓, decrease; ↔, no change. 
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CHAPTER FOUR 
DISCUSSION 
A high carbohydrate diet and a high fat diet are being blamed for the recent parallel 
epidemics of obesity, diabetes and hypertension. Some researchers are even 
suggesting that a high carbohydrate diet is more harmful than a high fat diet. The 
mechanisms by which a high carbohydrate diet induces diseases, especially 
cardiovascular diseases, are not entirely clear. Different research groups all over the 
world are studying different aspects of high carbohydrate induced metabolic changes. 
One of the mechanisms implicated for high carbohydrate-induced damage is an 
increase in oxidative stress (Turan and Vassort. 2011; Robertson and Harmon. 2006), 
while another mechanism involves O-GlcNAc modification of proteins, which is an 
reversible post-translational modification depends on glucose concentrations (Issad 
and Kuo. 2008).  
The main suspect and target for my research is MG, mainly generated from the 
glycolysis pathway, which is a reactive molecule and which is cytotoxic at higher 
concentrations. The western diet including high consumption of carbohydrates, 
especially fructose, increases MG production in the human body. Increased MG has 
been linked to diabetes mellitus and hypertension, and possibly obesity. MG-induced 
over-production of ROS and AGEs are thought to play important roles in MG-induced 
pathology. 
  Studies of acute and chronic MG treatment on SD rats have been performed to 
investigate the direct effects of MG on diabetes related parameters including plasma 
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glucose level, plasma insulin level, glucose uptake and some important proteins, such 
as glucose transporter-4 (GLUT-4) and phosphoinositide-3-kinase (Dhar et al. 2010a; 
Dhar et al. 2011) and MG was reported to alter these levels significantly and induce 
type 2 diabetes. Moreover, lipid parameters including free fatty acids, total cholesterol, 
HDL and triacylglycerols were also measured in the chronic study (Dhar et al. 2011) 
and significant abnormalities were reported with these parameters. To the best of my 
knowledge, this was the first study to report changes in plasma lipid levels induced by 
MG. However, the reason or the mechanism for changes in lipid levels was not 
investigated by collegues in our lab who performed that study. This was a novel and 
exciting observation and I undertook this project to investigate the mechanisms of 
MG-induced alterations in plasma lipid levels. In the study on acute in vivo effects of 
MG (Dhar et al. 2010a), MG levels in the liver increased significantly after a single 
i.p. injection of 17.25 mg/kg MG. In the study on chronic in vivo effects of MG (Dhar 
et al. 2011), a significant elevation of MG levels in adipose tissue and plasma in MG 
treated group was reported. Since the liver and the adipose tissue are major organs 
involved in lipid metabolism and plasma lipid level regulation, we decided to focus on 
these two organs to study the possible mechanism(s) which might be responsible for 
the the alterations of plasma lipid profiles. 
 
4.1 Effects of MG on adipose tissue and dyslipidemia 
   Regulation of lipid metabolism is a key function of the adipose tissue according to 
the energy homoeostasis requirement. There are three levels of regulation: fatty acid 
79 
 
uptake predominantly from circulation, lipogenesis from glucose to intracellular 
triacylglycerol and lipolysis to glycerol and fatty acid back to the circulation (Sethi 
and Hotamisligil. 1999). 
   In my study, abdominal adipocyte size was calculated after H-E staining and 
enlarged cell size was found in the abdominal adipose tissue from chronic MG treated 
group compared to control group, and co-treatment with AG prevented the increase in 
adipocyte cell size (Fig. 3-1). Abdominal adipocyte size itself is associated with 
substantial metabolic functions. Enlarged abdominal adipocyte size is the evidence of 
obesity and could also predispose to the onset of type 2 diabetes (Skurk et al. 2007; 
Weyer et al. 2000). Larger adipocytes are less sensitive to insulin and have lower 
ability to store triacylglycerols (Chui et al. 2005). Moreover, larger adipocytes were 
also found to have greater rate of lipogenesis from glucose as well as increased rate of 
lipolysis which may account for the elevated plasma fatty acid levels (Jacobsson and 
Smith. 1972).  
   The adipocyte comes from pre-adipocyte differentiation in which the C/EBPs 
family of proteins are the essential transcriptional factors to guarantee the successful 
outcome of this process. High levels of C/EBPα are normally expressed in the liver 
and the adipose tissue (Birkenmeier et al. 1989). C/EBPα is necessary for inducing 
differentiation of preadipocytes into mature adipocytes and C/EBPα knockout mice die 
within 7–12 h after birth, mainly due to defective gluconeogenesis in the liver (Wang et 
al. 1995). C/EBPα is especially required for the development of WAT (Linhart et al. 
2001).  
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In this study, C/EBPα and C/EBPβ protein levels were measured in both adipose 
tissue and 3T3-L1 adipocytes. Both C/EBPα and C/EBPβ protein levels increased 
significantly while the PPARγ expression did not change. Unlike the abundant 
expression of C/EBPα in the mature adipocyte, C/EBPβ expression dropped 50% by 
the late differentiation phase compared to its expression in the early stage of 
differentiation, and therefore our measurement of C/EBPβ in the mature adipocytes or 
adipose tissue from adult rats may be underestimated. However, the significant 
over-expression of C/EBPβ as well as C/EBPα could give us a clue that MG increases 
differentiation of pre-adipocytes. This hypothesis was also confirmed by Oil-Red O 
staining on 3T3-L1 cells in which we treated the pre-adipocytes with MG for 7 days 
until most of the cells became fully differentiated. Increased staining on oil droplet 
which mainly represents triacylglycerols could be the result of increased 
differentiation induced by MG. 
PPARγ is thought to be cross-regulated with C/EBPα and its expression in the 
adipose tissue begins at the early stage of differentiation and continues through the 
mature phase with important functions. PPARγ is the central engine of adipose 
differentiation and its activation initiates the full program of differentiation, including 
morphological changes, lipid accumulation and the expression of almost all genes 
related to adipocytes (Rosen and Spiegelman. 2006b). In the mature phase, the 
activation of PPARγ by its agonists, the TZDs, was found to improve fat storage and 
insulin sensitivity (Kersten et al. 2000). However, interestingly PPARγ selective 
antagonist was found to have anti-obesity and anti-diabetic effect by reducing the 
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adipocyte size and improving insulin sensitivity in the diabetic ob/ob mice (Rieusset et al. 
2002). In our study, PPARγ protein levels were measured in both tissue and mature 
adipocytes by western-blotting and the apparently increased levels found in the MG 
treated group were not significant. PPARγ agonists are reported to increase the adipocyte 
cell number and decrease the adipocyte cell size and therefore improve the fat storage 
(Johnson et al. 2007), which seems paradoxical with our findings on adipocyte cell size. 
MG-induced effects on other factors, which are involved in regulating fat storage in 
adipocyte and therefore regulating adipocyte cell size, such as TNFα might be an 
explanation of this paradox. 
TNFα is recognized as an inflammatory cytokine first found in the macrophage. 
However, TNFα is also highly expressed in the adipose tissue and is involved in lipid 
metabolism mainly by regulating several key enzymes and receptors, such as decreasing 
the expression of LPL, FFA receptor, GLUT4, acyl-CoA synthetase (ACS) and increasing 
the expression of hormone-sensitive lipase (HSL) (Sethi and Hotamisligil. 1999). 
Over-expression of TNFα leads to a decrease in fatty acid uptake; decrease in lipogenesis 
and increase in lipolysis, and the resultant elevation of FFAs in the circulation. PPARγ 
and TNFα have adverse effects on these proteins and thus further investigations on these 
proteins are important to answer this question clearly. However, in my study, LPL mRNA 
and protein levels did not show a significant difference between the control and MG 
treated groups. In a previous study from our lab, GLUT4 was found to be reduced in the 
chronic MG treated group which would lead to a decrease in lipogenesis and contribute to 
an increase in FFAs in the plasma. Thus, besides LPL protein expression, LPL activity 
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and other related protein levels or activity needs to be measured in the future. 
Another important group of mediators, which plays a role in lipid metabolism and 
plasma lipid level regulation, is the adipokines including leptin and adiponectin. Leptin is 
a hormone to control food intake and energy expenditure by acting on the leptin receptor 
in the CNS. Increased plasma leptin was found in obese subjects, along with a decrease in 
plasma HDL level in humans (Rainwater et al. 1997). TNFα is reported to increase leptin 
secretion while PPARγ to decrease its secretion. Adiponectin is a secreted exclusively by 
the adipose tissue and unlike other adipokines, the levels of adiponectin decrease in obese 
subjects. Adiponectin is thought to be an insulin enhancer and increased adiponectin is 
linked to increased triacylglycerol levels and decreased plasma levels of HDL (Kazumi et 
al. 2002). Opposite to its effect on the regulation on leptin, TNFα decreases the 
adiponectin levels while PPARγ increases it. We performed RT-PCR combined with 
ELISA or western blotting to investigate the levels of leptin in adipose tissue/plasma and 
adiponectin in adipose tissue. However, no significant difference was found in these two 
adipokines. The results were confirmed by experiments on cultured 3T3-L1 cells. No 
significant change in these two important adipokines might be explained by their 
co-regulation by multiple factors including PPARγ and TNFα.  
Insulin resistance is a term that cannot be avoided in evaluating this study. Enlarged 
adipocyte size and increased expression of TNFα are linked to insulin resistance and 
nearly all the adipocyte-related proteins are regulated by insulin. Chronic MG treated rats 
developed insulin resistance with reduced insulin levels as reported previously by our lab 
(Dhar et al. 2011). In the insulin resistance state, visceral adipocyte is more sensitive to 
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lipolytic hormones glucocorticoids and catecholamines and therefore increases the release 
of FFAs into the circulation which then serves as substrates for TG formation in the liver. 
Moreover, insulin resistance increases the production of apoB which leads to the 
elevation of apoB-rich lipoproteins (Kolovou et al. 2005). Based on our findings in this 
study and previous results, we suggest that MG-induced insulin resistance might be a 
mediator in MG-induced lipid alterations. 
AG, an AGEs scavenger, attenuated the effects of MG on adipocyte cell size, C/EBPα, 
C/EBPβ and TNFα expression in abdominal adipose tissue effectively. Even though AG 
is not a specific MG scavenger and has other actions (Desai and Wu. 2007), it is one of 
the most widely used compounds as a MG and AGEs scavenger due to a lack of 
availability of more specific agents. 
 
4.2 Effects of MG on the liver and dyslipidemia 
The liver plays a vital role in lipid metabolism and it is the center for fatty acid and 
lipoprotein synthesis. There are numerous studies which have investigated the effects of 
high carbohydrate, especially fructose, diet on lipid metabolism in the liver. When normal 
rats are fed with the high carbohydrate for a short time, increased triacylglycerol and 
FFAs levels were found in the rat plasma while insulin resistance also developed in the 
liver, skeletal muscle and adipose tissue. The possible mechanisms of fructose-induced 
dyslipidemia have been nicely reviewed by Basciano et al (Basciano et al. 2005) 
which includes the increased expression of lipoprotein secretion related genes such as 
MTP, the major fatty acid and cholesterol biosynthesis genes such as SREBP, the 
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increased lipolysis rates in visceral adipose depots and the decreased protection from 
lipid peroxidation and the resultant increased VLDL secretion and delayed clearance. 
In my study, we first examined the nuclear enzymes SREBP-1 and SREBP-2 which are 
the activators for mainly fatty acid synthesis and cholesterol synthesis, respectively. The 
expression of SREBP-2 increased significantly in the liver nuclear extract from chronic 
MG treated group, which was attenuated by co-treatment with AG. However, the 
expression of SREBP-1 did not change after MG treatment. SREBPs play a crucial role in 
maintaining the intracellular free cholesterol content. Thus, when the intracellular 
cholesterol concentration decreases in the hepatocyte, SREBPs attempt to bring it up to 
the required concentration in two ways: by increasing HMG-CoA reductase to synthesize 
more cholesterol, and by increasing LDL receptors on the hepatocyte which will pick up 
more cholesterol from the circulation into the liver. The SCAP protein described earlier in 
the introduction acts as a sterol sensor and an escort of SREBPs. When cholesterol level 
drops in the cell, SCAP enables cleavage of SREBPs to activate them and then guides the 
active SREBPs to the nucleus, where they switch on genes for cholesterol synthesis 
(HMG CoA reductase) and LDL receptor synthesis. The increase in HMG-CoA reductase 
observed in my study can be due to an increase in SREBP-2 or a direct effect of MG on 
HMG-CoA reductase. HMG-CoA is the rate-limiting enzyme in the cholesterol synthesis 
pathway. LDLR plays a key role in plasma LDL level regulation. LDLR transports LDL 
from cell surface to the lysosome through endocytosis. Impaired expression of LDLR and 
over-expression of HMG-CoA reductase have been linked to hypercholesterolemia (Yu et 
al. 1996; Pallottini et al. 2006). In this study, MG induced over-expression of HMG-CoA 
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reductase without affecting both mRNA and protein levels of LDLR. No change in LDLR 
despite an increase in SREBP-2, which can increase LDLR, needs further studies for an 
explanation. The increase in plasma cholesterol induced by MG (Dhar et al. 2011) can be 
explained by increased HMG-CoA reductase and increased cholesterol synthesis in the 
liver, and also by increased MTP activity and VLDL synthesis. 
 MTP is the last key enzyme we examined in the rat liver. It is essential for apoB 
100-containing lipoproteins assembly and its up-regulation leads to increased secretion of 
apoB-100 containing lipoproteins such as VLDL. In this study, MTP protein levels 
increased significantly in the liver of chronic MG-treated rats, which was attenuated by 
co-treatment with AG. The expression of MTP is negatively regulated by insulin, 
therefore chronic MG-induced MTP up-regulation might be due to decreased insulin 
levels in vivo, because chronic MG treated rats had significantly lower basal and 
glucose-stimulated plasma insulin levels (Dhar et al. 2011). 
Lipid metabolism in the liver is a complicated network and involves hundreds of 
enzymes and receptors. In this study, we chose five important ones to try to get a clue for 
MG-induced plasma lipid level alterations. Changes in SREBP-2, HMG-CoA and MTP 
protein levels might be the key mechanisms for MG-induced increased levels of total 
cholesterol and triacylglycerol in the plasma. 
 
4.3 Overall discussion 
  In this study, MG was infused continuously into adult SD rats for 28 days by an 
implanted minipump. MG levels increased in the adipose tissue and also created an 
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insulin resistance state. In chronic MG treated rats, abdominal adipocyte cell size 
increased and the expressions of C/EBPα and C/EBPβ as well as TNFα increased 
significantly. The overall effects of these alterations might result in increased lipolysis 
and decreased TG storage ability and therefore lead to increased FFAs in the plasma. 
FFAs in the plasma are substrates for TG synthesis in the liver. With the MG-induced 
up-regulation of SREBP-2, HMG-CoA reductase and MTP and enough supply of TG, 
cholesterols including VLDL, LDL production increases and therefore results in 
triacylglycerols and cholesterol increase in the plasma (Fig 4-1). 
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Figure 4-1. Possible mechanisms for MG-induced increase of FFAs, cholesterol 
and triacylglycerol levels in the plasma. 
Abbreviations: C/EBPs, CCAAT-enhancer binding proteins; FFAs, free fatty acids; 
HMGCR, 3-hydroxy-3-methyl glutaryl coenzyme A reductase; LDL, low density 
lipoprotein; MG, methylglyoxal; MTP, microsomal triacylglycerol transfer protein; 
SREBP, sterol regulatory element binding protein; TNFα, tumour necrosis factor α; 
VLDL, very low density lipoprotein. 
  
88 
 
CHAPTER FIVE 
CONCLUSIONS 
In chronic MG treated rats, the increase in fatty acids may be due to increased 
abdominal adipocyte size, elevated gene expression of TNFα and increased 
triacylglycerol accumulation caused by over-expression of C/EBPα, C/EBPβ and 
possibly PPARγ. Even though LPL protein and mRNA did not change, the activity of 
LPL needs to be checked. The increase in plasma cholesterol and triacylglycerols in 
chronic MG treated rats observed in the previous study from our lab (Dhar et al. 2011) 
may be due to increased expression of HMG-CoA reductase and the subsequent 
increased cholesterol synthesis; and due to increased MTP and the resultant increased 
VLDL synthesis in the liver. Further studies expanding on the current findings 
reported in my study will clarify the molecular mechanisms of altered plasma lipid 
levels induced by MG.
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